

CURRICULUM VITAE

JONATHAN L. HALPERIN, M.D.

OFFICE ADDRESS:

The Zena and Michael A. Wiener Cardiovascular Institute
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
Mount Sinai Medical Center
Fifth Avenue at 100th Street
New York, NY 10029

Telephone (212) 241-7243

Telecopier (212) 831-2195

Email jonathan.halperin@mssm.edu

jonathan.halperin@msnyuhealth.org

jonathan.halperin@mountsinai.org



EDUCATION:

1971 *A.B.* Columbia University, New York, New York

1975 *M.D.* Boston University, Boston, Massachusetts

Jonathan L. Halperin, M.D.

CURRENT APPOINTMENTS:

- 1996 - Robert and Harriet Heilbrunn Professor of Medicine (Cardiology)
Mount Sinai School of Medicine
New York University
- 1991 - Attending Physician in Medicine
Mount Sinai Hospital
New York, NY
- 1983 - Director, Clinical Cardiology Services
The Cardiovascular Institute
Mount Sinai Medical Center
- 1995 - Consultant Cardiologist
Clinical Program for Cerebrovascular Disorders
Mount Sinai Medical Center
- 1996 - Associate Director
The Zena and Michael A. Wiener Cardiovascular Institute
Mount Sinai Medical Center
- 2002 - Associate Director
The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health
Mount Sinai Medical Center
- 2005 - Director
Urban Community Cardiology Fellowship Training Program
Mount Sinai School of Medicine
- 2011 - Associate Director for Professional Development
Internal Medicine Residency Program
Mount Sinai School of Medicine

Jonathan L. Halperin, M.D.

POSTGRADUATE TRAINING:

- 1978 - 80 Fellow in Cardiology
University Hospital and Boston City Hospital
Boston, Massachusetts
- 1977 - 78 Clinical and Research Fellow
Peripheral Vascular Diseases
Evans Memorial Foundation for Clinical Research
Boston, Massachusetts
- 1976 - 77 Resident in Internal Medicine
University Hospital
Boston, Massachusetts
- 1975 - 76 Intern in Medicine
University Hospital
Boston, Massachusetts

ACADEMIC APPOINTMENTS:

- 1996 - Robert and Harriet Heilbrunn Professor of Medicine (Cardiology)
Mount Sinai School of Medicine
City University of New York
- 1993 - 2000 Professor of Medicine
Mount Sinai School of Medicine
City University of New York

PAST ACADEMIC APPOINTMENTS:

- 1986 - 93 Associate Professor of Medicine
Mount Sinai School of Medicine
City University of New York
- 1980 - 85 Assistant Professor of Medicine
Mount Sinai School of Medicine
City University of New York

Jonathan L. Halperin, M.D.

PAST ACADEMIC APPOINTMENTS - continued

- 1979 - 80 Howard B. Sprague Research Fellow
of the American Heart Association Massachusetts Affiliate, Inc.
- 1978 - 80 Teaching Assistant in Medicine
Boston University School of Medicine
Boston, Massachusetts
- 1976 - 78 Teaching Fellow in Medicine
Boston University School of Medicine
Boston, Massachusetts
- 1972 Research Assistant in Hematology
St. Elizabeth's Hospital
Brighton, Massachusetts
- 1971 Research Assistant in Hematology
Boston City Hospital
Boston, Massachusetts

PAST HOSPITAL APPOINTMENTS:

- 2006 - 10 Director
Program for Diagnostic and Preventive Medicine
Mount Sinai Heart
- 1983 - 93 Director of Clinical Services
Division of Cardiology
Mount Sinai Medical Center
- 1983 - 91 Associate Attending Physician for Cardiology
- 1980 - 85 Cardiology Liaison to the
Division of Cardiothoracic Surgery
Mount Sinai Medical Center
- 1978 - 80 Staff Physician
Lynn Hospital
Lynn, Massachusetts

Jonathan L. Halperin, M.D.

LICENSURE:

1977 Commonwealth of Massachusetts
Certificate No. (b) (6)

1979 State of New York
Certificate No. (b) (6)

CERTIFICATION:

1976 Diplomat
National Board of Medical Examiners

1980 Diplomat
American Board of Internal Medicine

1981 Diplomat
Subspecialty Board of Cardiovascular Disease

FELLOWSHIPS:

Fellow of the American College of Cardiology
Fellow of the American Heart Association
Master of the Society for Vascular Medicine
Fellow of the Council on Circulation of the American Heart Association
Fellow of the Council on Stroke of the American Heart Association
Fellow of the Council on Clinical Cardiology of the American Heart Association

BOARDS OF TRUSTEES, DIRECTORS AND GOVERNORS

American Board of Vascular Medicine (2004-present)
Member, Board of Governors
Executive Committee (2010-2013)
Secretary-Treasurer (2010-2013)

American Heart Association - New York City Affiliate (1997-2003)
President (1999-2001)
Leadership Development Committee (2003-2006)

Jonathan L. Halperin, M.D.

BOARDS OF TRUSTEES, DIRECTORS AND GOVERNORS - continued

- American Red Cross of Greater New York (1993-2007)
 - Gladys and Roland Harriman Society (2007)
 - Advisor to the Chair (1999-2000; 2006-2007)
 - Medical Advisor (1993-2007)
 - Governance and Nominating Committee (2005-2007)
 - Major Gifts Committee (2005-2007)
 - Financial Development Committee (2000-2005)
 - Executive Committee (1997-1999, 2001-2003)
 - Nominating Committee (2001-2003)

- Society for Vascular Medicine (1989-91; 1997-present)
 - Founding Trustee (1989-91)
 - Treasurer (1997-99)
 - President-Elect (1999-2001)
 - President (2001-2003)
 - Immediate Past-President (2003-2005)
 - Executive Committee on Certification in Vascular Medicine (2003-present)

- International Bicuspid Aortic Valve Registry & Tissue Bank
 - Board of Directors (2009-present)

- New York Cardiological Society (1991-1997)

SOCIETIES:

- American Association for the Advancement of Science (1980-present)
- American College of Cardiology (1983-present)
 - Clinical Quality Committee; Subcommittee on Science and Clinical Policy (2008-2011)
 - Document Oversight Committee (2008-2011)
 - American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence & Training (Vice-Chair, 2007-2008, Chair, 2008-2014)
 - Education Planning Summit (Delegate, 2007)
 - Writing Committee to Develop Guidelines for the Management of Patients with Extracranial Carotid and Vertebral Artery Disease (Co-Chair, 2006-2011)

Jonathan L. Halperin, M.D.

SOCIETIES - continued

- Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation (2005-2006)
- Task Force on Clinical Practice Guidelines (2004-2007; 2009-present)
- Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease (2002-2006)
- Task Force on Performance Measures for Physicians Managing Patients with Atrial Fibrillation (Co-Chair, 2003-2008)
- Writing Committee to Develop Clinical Data Standards for Atrial Fibrillation (2001-2003)
- Subspecialty Societies Leadership Committee (1999-2001)
- Writing Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation (2000-2001)
- Task Force on Clinical Expert Consensus Documents (1998-1999)
- Technology and Practice Executive Committee (1997-1998)
- American College of Physicians (1994-present)
- American Heart Association and American Stroke Association (1980-present)
 - Task Force on Clinical Practice Guidelines (2004-2007)
 - Council on Circulation (1993-present)
 - Council on Clinical Cardiology (1993-present)
 - National Spokespersons Panel (1998-present)
 - Program Committee (2003-2006)
 - Samuel Levine Award Committee (2003-2005)
- Stroke Council (1993-present)
 - Secondary Prevention Standing Committee (2004-2005)
 - Writing Committee to Develop Guidelines for Prevention of Stroke in Patients with Ischemic Stroke or Transient Ischemic Attack
- New York City Affiliate (1980-present)
 - President (1999-2001)
 - Board of Directors (1997-2001)
 - Council on Professional Education (1989-1991)
 - Stroke Section (1994-2001)
 - Vascular Committee (1982-1986)
- Heritage Affiliate (1998-present)
 - Stroke Task Force (1998-2001)
- American Federation for Clinical Research (1978-1985)

Jonathan L. Halperin, M.D.

SOCIETIES – continued

American Red Cross in Greater New York (1993-2007)
Board of Trustees (1993-2007)
Governance Committee (2005-2007)
Major Gifts Development Committee (2005-2007)
Nominating Committee (2001-2005)
Financial Development Committee (2001-2005)
Executive Committee (1995-2003)
Advisor to the Chair (1999-2000)
Medical Advisor (1993-2007)
American Society of Internal Medicine (1980-88)
New York Academy of Medicine (1982-present)
New York Academy of Sciences (1982-present)
New York Cardiological Society (1981-present)
Board of Governors (1989-1997)
Committee on Programs (1994-1996)
New York County Medical Society (1993-present)
New York State Medical Society (1993-present)
New York State Society of Internal Medicine (1993-present)
North American Society of Pacing and Electrophysiology (1980-85)
Physicians for Social Responsibility (1978-1984)
Society for Vascular Medicine (1989-present)
Master of the Society (2009-present)
Executive Committee on Certification in Vascular Medicine (2003-2007)
Immediate Past-President (2003-2005)
President (2001-2003)
President-elect (1999-2001)
Treasurer (1997-99)
Founding Trustee (1989-91)

FEDERAL APPOINTMENTS

U.S. Food and Drug Administration

Cardiovascular and Renal Drugs Advisory Committee

2009-2012

Jonathan L. Halperin, M.D.

FEDERAL APPOINTMENTS - continued

National Institutes of Health - National Heart, Lung & Blood Institute

Clinical Trial of Aspirin and Simvastatin in Pulmonary
Arterial Hypertension (ASA-STAT)
Data Safety Monitoring Board 2006-2010

Randomized Trial of Genotype-Guided Warfarin Dosing
Review Panel for NHLBI Request for Proposals HV-08-03
Clinical Trial Coordinating Center 2007

EDITORIAL BOARDS:

Mount Sinai Journal of Medicine 2009-present
www.theheart.org 2000-present
Cardiology 2005-2008

EXTRAMURAL AWARDS and HONORS:

Master of the Society for Vascular Medicine 2009

The Heart of New York Award 2005
Presented by the American Heart Association Heritage Affiliate
For Achievement in Cardiovascular Science and Medicine

The Heart of New York Presidential Salute 2002
American Heart Association Heritage Affiliate

Howard B. Sprague Research Fellowship Award 1979
American Heart Association Massachusetts Affiliate

INTRAMURAL AWARDS and HONORS:

Cardiology Fellows Appreciation Award 2010
For Exceptional Dedication, Support and Advocacy on
Behalf of the Fellows

Jonathan L. Halperin, M.D.

INSTITUTIONAL AWARDS and HONORS – continued:

Samuel Bronfman Department of Medicine Teaching Excellence Award Presented by the Chairman for Teaching of House Staff	2006, 2007
Samuel Bronfman Department of Medicine Grand Rounds Award Presented by the Chairman to the best Grand Rounds speaker During the 2006-2007 academic year	2007
Cardiology Fellows Society of Greater New York Award for Outstanding Support for Cardiovascular Education And Research	2006
The Simon Dack Award Presented by the fellows, Mount Sinai Hospital For Teaching in Cardiology	1986, 2006
The Jacobi Medallion Presented by the Associated Alumni of the Mount Sinai Hospital For Distinguished Achievement in Medicine and Extraordinary Service Mount Sinai School of Medicine	2002
The Solomon R. Berson Memorial Award Presented by the house staff of the Mount Sinai Hospital To the Outstanding Teacher in the Department of Medicine	1988
John R. Murray Award For Achievement in Clinical Psychiatry Boston University School of Medicine	1975
The University Hospital Chair For Achievement in Clinical Medicine Boston University School of Medicine	1975
Roland Jackson Memorial Medical Scholarship For Studies in Medicine Swampscott, Massachusetts	1972, 1973, 1974

Jonathan L. Halperin, M.D.

PUBLICATIONS

ORIGINAL PEER-REVIEWED REPORTS:

1. Quesenberry P, Niskanen E, Symann M, **Halperin JL**, Ryan M, Howard D, Stohlman F. Growth of stem cell concentrates in diffusion chambers. *Cell Tissue Kinet* 1974; 7: 337-48.
2. Quesenberry P, **Halperin JL**, Ryan M, Stohlman F. Tolerance to the granulocyte-releasing and colony-stimulating factor elevating effects of endotoxin. *Blood* 1975; 45: 789-800.
3. Faxon DP, Creager MA, **Halperin JL**, Gavras H, Coffman JD, Ryan TJ. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory heart failure. *Circulation* 1980; 61: 925-939.
4. Faxon DP, Creager MA, **Halperin JL**, Gavras H, Schick EC, Ryan TJ. Angiotensin inhibition in severe heart failure: Acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. *Am Heart J* 1981; 101: 548-556.
5. Creager MA, **Halperin JL**, Faxon DP, Bernard DB, Melidossian CD, Gavras H, Ryan TJ. Acute regional circulatory and renal hemodynamic effects of converting enzyme inhibition in patients with congestive heart failure. *Circulation* 1981; 64: 483-489.
6. Creager MA, Faxon DP, **Halperin JL**, Melidossian CD, McCabe CH, Schick EC, Ryan TJ. Determinants of clinical response and survival in patients with congestive heart failure treated with captopril. *Am Heart J* 1982; 104: 1147-1154.
7. Faxon DP, Creager MA, **Halperin JL**. Regional circulatory response to converting enzyme inhibition in congestive heart failure. *Br J Clin Pharmacol* 1982; 14: 179S-186S.
8. **Halperin JL**, Faxon DP, Creager MA, Bass TA, Melidossian CD, Gavras H, Ryan TJ. Coronary hemodynamic effects of angiotensin inhibition in patients with congestive heart failure. *Am J Cardiol* 1982; 50: 967-972.
9. Faxon DP, Creager MA, **Halperin JL**, Sussman HA, Gavras H, Ryan TJ. The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. *Int J Cardiol* 1982; 2: 251-262.
10. Creager MA, **Halperin JL**, Klein MD, Coffman, JD. Peripheral arterial and venous effects of acetylserophanthidin in patients with acute myocardial infarction. *Clin Pharmacol Ther* 1982; 32: 736-743.

Jonathan L. Halperin, M.D.

ORIGINAL PEER-REVIEWED REPORTS - continued

11. **Halperin JL**, Cohen RA, Coffman JD. Vasodilatation during mental stress in patients with Raynaud's Disease. *Cardiovasc Res* 1983; *17*: 671-677.
12. Reder RF, Mindich BP, **Halperin JL**, Litwak RS, Kupersmith J. Acute effects of oral labetalol on myocardial conduction following coronary artery bypass graft surgery. *Clin Pharmacol Ther* 1984; *35*: 454-460.
13. **Halperin JL**, Camunas JL, Stern EH, Rothlauf EB, Estioko MR, Mace RC, Steinmetz MY, Kupersmith J, Teichholz LE. Myopotential interference with DDD pacemakers: endocardial electrographic telemetry in the diagnosis of pacemaker-related arrhythmias. *Am J Cardiol* 1984; *54*: 97-102.
14. **Halperin JL**, Brooks KM, Rothlauf EB, Mindich BP, Ambrose JA, Teichholz LE. Effect of nitroglycerin on the pulmonary venous gradient in patients following mitral valve replacement. *J Am Coll Cardiol* 1985; *5*: 34-39.
15. **Halperin JL**, Mindich BP, Rothlauf EB, Reder RF, Litwak RS, Kupersmith J. Effect of labetalol on limb hemodynamics in patients following coronary artery bypass graft surgery. *Br J Clin Pharmacol* 1986; *21*: 537-542.
16. **Halperin JL**, Rothlauf EB, Mindich BP, Brooks KM, Ambrose JA. Effect of nitroglycerin during hemodynamic estimation of valve orifice in patients with mitral stenosis. *J Am Coll Cardiol* 1987; *10*: 342-348.
17. Paris BEC, Libow LS, **Halperin JL**, Mulvihill MN. The prevalence and one-year outcome of limb arterial obstructive disease in a nursing home population. *J Am Geriatr Soc* 1988; *36*: 607-612.
18. Weinberger J, Rothlauf EB, Materese E, **Halperin JL**. Noninvasive evaluation of the extracranial carotid arteries in patients with cerebrovascular events and atrial fibrillation. *Arch Intern Med* 1988; *148*: 1785-1788.
19. **Halperin JL**, Rothlauf EB, von Polnitz A. Limb hemodynamic effects of pentoxifylline in patients with intermittent claudication. *J Vasc Med Biol* 1989; *1*: 294-299.
20. Stroke Prevention in Atrial Fibrillation Study Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med* 1990; *322*: 863-868.

Jonathan L. Halperin, M.D.

ORIGINAL PEER-REVIEWED REPORTS - continued

21. Stroke Prevention in Atrial Fibrillation Study Investigators. Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation study. *Stroke* 1990; 21: 538-543.
22. Stroke Prevention in Atrial Fibrillation Study Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. *Circulation* 1991; 84: 527-539.
23. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Study. *Ann Intern Med* 1992; 116: 1-5.
24. Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Study. *Ann Intern Med* 1992; 116: 6-12.
25. Flaker GC, Blackshear JL, McBride R, Kronmal RA, **Halperin JL**, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. *J Am Coll Cardiol* 1992; 20: 527-532.
26. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of arterial thromboembolism in atrial fibrillation: Design and patient characteristics of the Stroke Prevention in Atrial Fibrillation II Study. *Cerebrovasc Dis* 1992; 2: 332-341.
27. Stroke Prevention in Atrial Fibrillation Investigators. A differential effect of aspirin in the Stroke Prevention in Atrial Fibrillation study. *J Stroke Cerebrovasc Dis* 1993; 3: 181-188.
28. Blackshear JL, Pearce LA, Asinger RW, Dittrich HC, Goldman ME, Zabalgoitia M, Rothbart RM, **Halperin JL**. Mitral regurgitation protects against thromboembolic events in patients with atrial fibrillation. *Am J Cardiol* 1993; 72: 840-843.
29. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin compared to aspirin for prevention of thromboembolism in atrial fibrillation: Results of the Stroke Prevention in Atrial Fibrillation II study. *Lancet* 1994; 343: 687-691.
30. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. *Arch Intern Med* 1994; 154: 1449-1457.

Jonathan L. Halperin, M.D.

ORIGINAL PEER-REVIEWED REPORTS - continued

31. Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. *Arch Intern Med* 1996; 156: 409.
32. Stroke Prevention in Atrial Fibrillation Investigators, Committee on Echocardiography. Transesophageal echocardiography in atrial fibrillation: Standards for acquisition and interpretation and assessment of inter-observer variability. *J Am Soc Echocardiogr* 1996; 9: 556-566.
33. Flaker GC, Fletcher KA, Rothbart RM, **Halperin JL**, Hart RG for the Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Clinical and echocardiographic features of intermittent atrial fibrillation which predict recurrent atrial fibrillation. *Am J Cardiol* 1995; 76: 355.
34. Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. *J Stroke Cerebrovasc Dis* 1995; 5: 147-157.
35. Weintraub WS, Mauldin PD, Talley JD, Diamond GA, Merlino J, Lindsay J, Bodenheimer MM, DeMaio S, Klein LW, Faxon DP, O'Neill WW, Williams D, Ivanhoe R, Stillabower M, Buda A, **Halperin JL**, Vogel R. Determinants of hospital charges and costs in acute myocardial infarction: A report from the Myocardial Infarction Cost Study (MICS) Group. *Am J Man Care* 1996; 2: 977-986.
36. Stroke Prevention in Atrial Fibrillation Investigators. The Stroke Prevention in Atrial Fibrillation III randomized clinical trial: Background, design and patient characteristics of the Stroke Prevention in Atrial Fibrillation III study. *J Stroke Cerebrovasc Dis* 1997; 6: 341-353.
37. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet* 1996; 348: 633-638.
38. Atrial Fibrillation Investigators. The efficacy of aspirin in patients in atrial fibrillation: Analysis of pooled data from three randomized trials. *Arch Intern Med* 1997; 157: 1237-1240.

Jonathan L. Halperin, M.D.

ORIGINAL PEER-REVIEWED REPORTS - continued

39. CAPRIE Steering Committee (on behalf of the CAPRIE Study Group). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). *Lancet* 1996; 348:1329-39.
40. Stroke Prevention in Atrial Fibrillation Investigators, Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation. *Ann Intern Med* 1998; 128:639-647.
41. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997; 350: 389-96.
42. Dittrich HC, Pearce LA, Cushing K, Asinger RW, McBride R, Webel R, Zabalgaitia M, Pennock GD, Safford RE, Rothbart RM, **Halperin JL**, Hart RG on behalf of the Stroke Prevention in Atrial Fibrillation Investigators. Left atrial diameter in nonvalvular atrial fibrillation: An echocardiographic study. *Am Heart J* 1999; 137:494-499.
43. Stroke Prevention in Atrial Fibrillation Investigators. Prospective identification of patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation Study. *JAMA* 1998; 279: 1273-1277.
44. The Steering and Publications Committee of the ACUTE study for the ACUTE Investigators. Design of a clinical trial for the assessment of cardioversion using transesophageal echocardiography (The ACUTE multicenter study). *Am J Cardiol.* 1998; 81:877-83.
45. Zabalgaitia M, **Halperin JL**, Pearce, LA, Blackshear JL, Asinger RW, Hart RG for the Stroke Prevention in Atrial Fibrillation Investigators. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. *J Am Coll Cardiol* 1998; 31: 1622-1626.
46. Asinger RW, Koehler J, Pearce LA, Zabalgaitia M, Blackshear JL, Fenster PE, Strauss R, Hess D, Pennock GD, Rothbart RM, **Halperin JL** for the Stroke Prevention in Atrial Fibrillation Investigators. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: II. Dense spontaneous echo-contrast. *J Am Soc Echocardiogr* 2000; 12:1088-1096.

Jonathan L. Halperin, M.D.

ORIGINAL PEER-REVIEWED REPORTS - continued

47. Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1,066 patients from three clinical trials. *Arch Intern Med* 1998; 158:1316-1320.
48. Blackshear JL, Zabalgoitia M, Pennock GD, Fenster PE, Strauss R, **Halperin JL**, Asinger RW, Pearce, LA for the Stroke Prevention in Atrial Fibrillation Investigators. Warfarin safety and efficacy in patients with thoracic aortic plaque and atrial fibrillation. *Am J Cardiol* 1999; 83:453-5.
49. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Labovitz A, **Halperin JL**, Committee on Echocardiography, Stroke Prevention in Atrial Fibrillation Investigators. Aortic plaque in atrial fibrillation: Prevalence, predictors and thromboembolic implications. *Stroke* 1999; 30: 834-840.
50. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, **Halperin JL** for the Stroke Prevention in Atrial Fibrillation Investigators. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage. *J Am Soc Echocardiogr* 1999; 12:1080-1087.
51. Hart RG, **Halperin JL**, McBride R, Benavente O, Man-Son-Hing, M, Kronmal R. Aspirin for primary prevention of stroke and major vascular events: Meta-analysis and hypotheses. *Arch Neurol* 2000; 57:326-332.
52. Pearce LA, Hart RG, **Halperin, JL**. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. *Am J Med* 2000; 109:45-51.
53. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, **Halperin JL**. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy. *J Am Coll Cardiol* 2000; 35:183-187.
54. Hart RG, **Halperin JL**: Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention. *Ann Intern Med* 1999; 131: 688-695.
55. Farkouh ME, Robbins MJ, Zafar MU, Shimbo D, Davidson KW, Puttappa R, **Halperin JL**, Epstein EM, Patel M, Talor Z, Chesebro JH: Association between troponin-I levels and mortality stable hemodialysis patients. *Am J Med* 2003; 114:224-226.

Jonathan L. Halperin, M.D.**ORIGINAL PEER-REVIEWED REPORTS – continued**

56. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, **Halperin JL**, Orsinelli DA, Porter TR, Stoddard MF for the ACUTE Investigators. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. *N Engl J Med* 2001; 344: 1411-1420.
57. Gomberg-Maitland M, Frison L, **Halperin JL**. Active-control clinical trials to establish equivalence or non-inferiority: Methodological and statistical concepts linked to quality. *Am Heart J*; 2003; 146: 398-403.
58. Hart RG, **Halperin JL**, Pearce LA, Anderson DC, Kronmal RA, McBride R, Nasco E, Sherman DG, Talbert RL, Marler JR on behalf of the Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke Prevention in Atrial Fibrillation Trials. *Ann Intern Med* 2003; 138: 831-838.
59. **Halperin JL**, and The Executive Steering Committee, on behalf of the SPORTIF III and V Study Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). *Am Heart J* 2003; 146: 431–8.
60. The Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation: The SPORTIF III trial. *Lancet* 2003; 362: 1691-1698.
61. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, **Halperin JL**, Horrow J, Olsson SB, Petersen P, Vahanian A. The Executive Steering Committee on behalf of the SPORTIF V Investigators. Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: The SPORTIF V randomized trial. *JAMA* 2005; 293: 690-8.
62. Klein AL, Grimm RA, Jasper SE, Murray D, Apperson-Hansen C, Lieber EA, Black IW, Davidoff R, Erbel R, **Halperin JL**, Orsinelli DA, Porter TR, Stoddard MF. Efficacy of transesophageal echocardiography guided cardioversion of patients with atrial fibrillation at 6 months: A randomized controlled trial. *Am Heart J* 2006;151: 380-9.

Jonathan L. Halperin, M.D.**ORIGINAL PEER-REVIEWED REPORTS - continued**

63. Diener H-C and the Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation: Pooled analysis from the SPORTIF III and V studies. *Cerebrovasc Dis* 2006; 21:279–293.
64. Nair AJ, Nemirovsky D, Kim M, Geer EB, Farkouh ME, Winston J, Epstein E, Schwartz D, Patel M, **Halperin JL**, Robbins MJ. Elevated homocysteine levels in patients with end-stage renal disease. *Mount Sinai J Med* 2005; 72: 365-373.
65. Gomberg-Maitland M, Wenger NK, Feyzi J, Lengyel M, Volgman A, Petersen P, Frison L, **Halperin JL**. Anticoagulation in women with nonvalvular atrial fibrillation in the Stroke Prevention Using an Oral Thrombin Inhibitor (SPORTIF) trials. *Eur Heart J* 2006; 27:1947-1953.
66. Flaker G, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, **Halperin JL** and the SPORTIF Investigators. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: An exploratory analysis of the Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation (SPORTIF) trials. *Am Heart J* 2006; 152: 967-73.
67. Stein R, Hriljac I, Gustavson SM, Teodorescu V, **Halperin JL**, Olin JW. Limitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial disease. *Vasc Med* 2006; 11: 29-33.
68. Hart RG, Albers GW, Connolly SJ, Friday G, Gage BF, Go AS, Goldstein LB, Gronseth G, **Halperin JL**, Hylek EM, Lip GYH, Pearce LA, Sherman DG, Singer, van Walraven C. (Stroke Risk in Atrial Fibrillation Working Group). Prediction of stroke in patients with atrial fibrillation: Systematic review of independent predictors and absolute stroke rates. *Neurology* 2007; 69:546-554.
69. Freudenberger RS, **Halperin JL**, Poole J, Anderson J, Hellkamp A, Mark DB, Lee KL, Bardy GH for the SCD-HeFT Investigators. Heart failure and thromboembolism: An analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). *Circulation* 2007; 115: 2637-2641.
70. Syed T, **Halperin JL**. Closing the left atrial appendage to prevent thromboembolism in patients with atrial fibrillation: State of the art and current challenges. *Nature Clin Prac Cardiovasc Med* 2007; 4:428-435.

Jonathan L. Halperin, M.D.**ORIGINAL PEER-REVIEWED REPORTS – continued**

71. Goldberg SH, **Halperin JL**. Arterial and ventricular factors governing management of aortic regurgitation. 2008; 5: 269-279.
72. The AMADEUS Investigators. Comparison of vitamin K antagonists with idraparinux for prevention of thromboembolism in patients with atrial fibrillation. *Lancet* 2008; 371: 315–321.
73. Hart RG, Albers GW, Connolly SJ, Friday G, Gage BF, Go AS, Goldstein LB, Gronseth G, **Halperin JL**, Hylek EM, Lip GYH, Pearce LA, Sherman DG, Singer, van Walraven C. (Stroke Risk in Atrial Fibrillation Working Group). Comparison of 12 Risk Stratification Schemes to Predict Stroke in Patients with Nonvalvular Atrial Fibrillation. *Stroke* 2008; 39:1901-1910.
74. Rubboli A, **Halperin, JL**, Airaksinen J, Buerke M, Eeckhout E, Freedman B, Gershlick AH, Schlitt A, Tse HF, Verheugt FWA, Lip GHY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting: an expert consensus document with focus on atrial fibrillation. *Ann Med* 2008; 40:428-36. ISSN 0785-3890; DOI: 10.1080/07853890802089786; (<http://dx.doi.org/10.1080/07853890802089786>).
75. Scott SA, Jaremko M, Lubitz SA, Kornreich R, **Halperin JL**, Desnick RJ. *CYP2C9*8* is prevalent in African-Americans: Implications for pharmacogenetic dosing. *Pharmacogenomics* 2009; 10: 1243-55.
76. Ip J, Waldo AL, Lip GYH, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS, Rohani P, **Halperin JL** on behalf of the IMPACT Investigators. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in patients with ICD and CRT-D devices: Rationale, design and clinical characteristics of the initially enrolled cohort. The IMPACT Study. *Am Heart J* 2009; 158: 364-370.
77. Elmariah S, Delaney JAC, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, Kronmal RA, **Halperin JL**. Bisphosphonate use and the prevalence of cardiovascular calcification in women: The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol* 2010; 58; 1752-9.
78. Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I, Doheny D, van der Zee S, Jaremko M, Desnick RJ, **Halperin JL**. Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. *J Thromb Haemost* 2010; 8: 1018-1026. (e-published February 1, 2010; DOI: 10.1111/j.1538-7836.2010.03792.x).

Jonathan L. Halperin, M.D.**ORIGINAL PEER-REVIEWED REPORTS** – continued

79. Baber U, Howard VJ, **Halperin JL**, Soliman EZ, Zhang X, McClellan W, Warnock DG, Muntner P. Association of Chronic Kidney Disease with Atrial Fibrillation among Adults in the United States. *Circ Arrhythm Electrophysiol* 2010; (e-published ahead of print)
80. Lip GYH, **Halperin JL**. Improving stroke risk stratification in atrial fibrillation. *Am J Med* 2010;123:484-488.
81. The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators. Rivaroxaban – once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: Rationale and design of the ROCKET AF study. *Am Heart J* 2010; 159: 340-347.
82. Hart RG, Pearce LA, Aguilar MI, **Halperin JL**. Meta-analysis: Antithrombotic therapy to prevent stroke in patients with atrial fibrillation – An update. 2010 (submitted for publication).
83. Lip GYH, Frison L, **Halperin JL**, Lane DA. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. *Stroke* 2010; 41:2731-2738.
84. Lip GYH, Frison L, **Halperin JL**, Lane DA. Comparative validation of a novel risk score [HAS-BLED] for predicting bleeding risk in anticoagulated patients with atrial fibrillation. *J Am Coll Cardiol* 2010; 57:173-180 (e-published November 24, 2010).
85. Elmariah S, Delaney JAC, Bluemke JA, Budoff MJ, O'Brien KD, Fuster V, Kronmal RA, **Halperin JL**. Increased Left Ventricular Mass Predicts Incident Aortic and Mitral Valve Calcification: The Multi-Ethnic Study of Atherosclerosis. 2011 (submitted for publication).
86. Viles-Gonzalez JF, Fuster V, **Halperin JL**, Calkins H, Reddy VY. Rhythm control for management of patients with atrial fibrillation: Balancing the use of anti-arrhythmic drugs and catheter ablation. *Clin Cardiol* 2011; (in press).
87. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, **Halperin JL**, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini J, Berkowitz SD, Fox KAA, Califf RM and the ROCKET AF Steering Committee on behalf of the ROCKET AF Investigators. Prevention of stroke and systemic embolism using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: The ROCKET AF trial. 2011; (submitted for publication).

Jonathan L. Halperin, M.D.

CLINICAL CASE REPORTS:

- R-1. Squire A, Miller CM, Horowitz SF, Shane L, Jacobson JH, **Halperin JL**. Femoral pseudoaneurysm following nonpenetrating trauma in a patient with aortic insufficiency. *Am J Med* 1985; 78: 719-720.
- R-2. Coplan NL, Ambrose JA, **Halperin JL**. Unilateral neck pulsations in a patient with a permanent pacemaker. *Chest* 1985; 87: 548-550.
- R-3. Coplan NL, Goldman B, Mechanic G, Mazzuchhi F, **Halperin JL**. Sudden hemodynamic collapse following relief of cardiac tamponade in a patient with aortic dissection. *Am Heart J* 1986; 111: 405-406.
- R-4. Stern A, Novack H, Mindich BP, **Halperin JL**. Extraluminal compression of an aortic graft simulating recoarctation. *Br Heart J* 1987; 57: 286-288.
- R-5. Keohane ME, Lazzam CL, Strauchen JA, Ergin AM, **Halperin JL**. Angiosarcoma of the left atrium. *Hum Pathol* 1988; 20:599-601.
- R-6. Hauptman PJ, Cosico J, **Halperin JL**. Cardiographic conundrum: Dextrocardia. *Heart and Lung* 1992; 21:192-195.
- R-7. Lebowhl M, **Halperin JL**, Phelps RG. Occult pseudoxanthoma elasticum in patients with premature cardiovascular disease. *N Engl J Med* 1993; 329: 1237-1239.
- R-8. **Halperin JL**. Case Records of the Massachusetts General Hospital: Weekly clinicopathological exercise, differential diagnosis. *N Engl J Med* 1999; 341:1829-1835.
- R-9. Chaudhari PR, Abergel J, Warner RR, Love BA, **Halperin JL**, Zacks J, Adler E. Left-sided carcinoid heart disease: A case report and review of the literature. *Nature Clin Prac Cardiovasc Med* 2007; 4: 455-9.
- R-10. Sealove BA, Aledort LM, Stacy, CB, **Halperin JL**. Recurrent orthostatic global amnesia in a patient with postoperative hyperfibrinogenemia. *J Stroke Cerebrovasc Dis* 2008; 17: 241-243.
- R-11. Vendanthan R, Sanz, **Halperin JL**. Bicuspid pulmonic valve. *J Am Coll Cardiol* 2009; 54: e5.

Jonathan L. Halperin, M.D.

CLINICAL CASE REPORTS - continued

R-12. Trost B, **Halperin JL** Unstable angina in a patient with anomalous origin of the left main coronary artery from the right sinus of Valsalva. *Rev Cardiovasc Med* 2010; 11:112-116.

APPEARS THIS WAY ON ORIGINAL

Jonathan L. Halperin, M.D.

BOOKS:

- B-1. **Halperin JL**, Levine R. *BYPASS: A Cardiologist Reveals What Every Patient Needs To Know*. New York: Times Books -- Random House, 1985 (ISBN: 0812911571; Dewey: 617/.412 19; LCCN: RD598.H28 1985); Phoenix: The Body Press -- HP Books, 1987 (ISBN: 0895865092; Dewey: 617/.412 19; LCCN: RD598.H28 1987).
- B-2. Gross PA, **Halperin JL**, Lipkin M, Marks JH, Rivlin RS, Wise TN, Grzelka C. *Managing Your Health: Strategies for Lifelong Good Health*. Yonkers, NY: Consumer Reports Books, 1991.
- B-3. Connolly SJ, Gore JL, **Halperin JL**. *Aligning Clinical Practice with Evidence for Prevention of Thromboembolism in Atrial Fibrillation*. Institute for Continuing Healthcare Education, 2002.

CHAPTERS IN BOOKS:

- C-1. Quesenberry P, Morley A, Bealmear P, Niskanen E, **Halperin JL**, Ryan M, Howard D, Stohlman F. Studies of endotoxin-induced colony stimulating factor elevations. In *Hemopoiesis in Culture: Second International Workshop*, edited by WA Robinson. DHEW Publication No. (NIH) 74-205, 1973, pp. 126-133.
- C-2. **Halperin JL**. Thrombophlebitis in obstetrics and gynecology. In *Current Therapy*, 35th Edition, edited by HLF Conn. Philadelphia: W.B. Saunders, 1983, pp. 885-889.
- C-3. Silvey G, **Halperin JL**. The electrocardiogram following cardiac surgery. In *EKG for Anesthesia and Critical Care*, edited by JA Kaplan and DM Thys. New York: Churchill Livingstone, 1987, pp. 203-224.
- C-4. **Halperin JL**. Collagen diseases and the heart. In *Cardiology*, edited by WW Parmley and K Chatterjee. Philadelphia: J.B. Lippincott, 1987, Ch 70, pp. 1-23.
- C-4a. **Halperin JL**. Collagen diseases and the heart. In *Cardiology*, 2nd edition, WW Parmley and K Chatterjee, editors. Philadelphia: J.B. Lippincott, 1991, Ch 110, pp. 13.2-13.18.
- C-5. **Halperin JL**. Raynaud's phenomenon and related forms of cutaneous vasospasm. In *Difficult Diagnoses in Dermatology*, edited by M Lebwohl. New York: Churchill Livingstone, 1988, pp. 45-63.

Jonathan L. Halperin, M.D.

CHAPTERS – continued

- C-6. **Halperin JL.** Noninvasive vascular laboratory evaluation: Applications for laser angioplasty, In: *Laser Angioplasty*, edited by T. Sanborn. New York: Alan R Liss, Inc., 1989, pp. 7-14.
- C-7. Stein B,**Halperin JL**, Fuster V. Should patients with atrial fibrillation receive anticoagulants prior to cardioversion? In *Dilemmas in Clinical Cardiology*, edited by MD Cheitlin. *Cardiovasc Clin* 1990; 21:231-249.
- C-8. Phillips RA,**Halperin JL**. Preoperative assessment and preparation of the urologic patient: A. The patient with cardiac disease. In *Surgical Management of Urologic Disease: An Anatomic Approach*, edited by MJ Droller, St. Louis: Mosby-Year Book Inc, 1992, pp. 5-12.
- C-9. Creager, MA, Coffman JD,**Halperin JL**. Vasospastic Diseases and other disorders related to temperature. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co. 1992, pp. 975-1010.
- C-10. **Halperin JL**, Creager MA. Arterial obstructive diseases of the extremities. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co.1992, pp. 835-866.
- C-11. Creager MA, **Halperin JL**, Whittmore AD. Aneurysmal disease of the aorta and its branches. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co. 1992, pp. 903-930.
- C-12. **Halperin JL**. Taking care of your heart. In *Managing Your Health: Strategies for Lifelong Good Health*, edited by PA Gross, JL Halperin, M Lipkin, JH Marks, RS Rivlin, TN Wise, C Grzelka. Yonkers, NY: Consumer Reports Books 1991, pp. 50-78.
- C-13. **Halperin JL**, Petersen P. Thrombosis in the cardiac chambers: Atrial fibrillation and left ventricular dysfunction. In *Thrombosis in Cardiovascular Diseases*, edited by V Fuster, M Verstraete. Philadelphia: WB Saunders 1992, pp. 215-236.
- C-14. **Halperin JL**, Hart RG. Atrial fibrillation without valvular heart disease. In *Thrombosis, Embolism and Bleeding*, edited by EG Butchart, E Bodnar. London: ICR Publishers 1992, pp. 16-30.
- C-15. Creager MA,**Halperin JL**. Aortic and arterial aneurysms. In *Atlas of Heart Diseases*, edited by E Braunwald. Philadelphia: Current Medicine, volume 7, 1996; pp. 1.1-1.19.

Jonathan L. Halperin, M.D.

CHAPTERS - continued

- C-16. Creager, MA, **Halperin JL**, Coffman JD. Raynaud's phenomenon and other vascular disorders related to temperature. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, 2nd edition, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co. 1996, pp. 965-998.
- C-17. Creager MA, **Halperin JL**, Whittimore AD. Aneurysmal disease of the aorta and its branches. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, 2nd edition, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co. 1996, pp. 901-926.
- C-18. **Halperin JL**. Noncoronary atherosclerosis: Atherosclerotic diseases of the aorta. In *Atherosclerosis and Coronary Artery Disease*, edited by V Fuster, R Ross, EJ Topol. Philadelphia: Raven Press 1996, pp. 1625-1642.
- C-19. **Halperin JL**, Creager MA. Arterial obstructive diseases of the extremities. In *Vascular Medicine: A Textbook of Vascular Biology and Diseases*, 2nd edition, edited by J Loscalzo, MA Creager, VJ Dzau. Boston: Little, Brown & Co. 1996, pp. 825-854.
- C-20. **Halperin JL**. Management of cardiac disorders with antithrombotic agents. In *The Pharmacologic Management of Heart Disease*, edited by J Kupersmith and P C Deedwania. Baltimore: Williams & Wilkins Co. 1996, pp. 303-340.
- C-21. Creager MA, **Halperin JL**. Aortic and arterial aneurysms. In *Slide Atlas of Heart Diseases: Vascular Disease*, edited by E Braunwald and M. A. Creager. London: Current Medicine, volume 7, 1996; Section 1.
- C-22. **Halperin JL**. Cardiac ultrasound in stroke investigation. In *Primer on Cerebrovascular Diseases*, edited by KMA Welch, LR Caplan, DJ Reis, BK Siesjo, B Weir. San Diego: Academic Press, 1997; pp. 624-628.
- C-23. **Halperin JL**, Petersen P. Thrombosis in the cardiac chambers: Atrial fibrillation and ventricular dysfunction. In *Cardiovascular Thrombosis: Thrombocardiology*, edited by M Verstraete, V Fuster, EJ Topol. Philadelphia: Lippincott-Raven, 1998; pp 415-438.
- C-24. **Halperin JL**. Collagen diseases and the heart. In *Cardiology: An Illustrated Text/Reference*, 3rd edition, WW Parmley and K Chatterjee, editors. Philadelphia: J.B. Lippincott, 1998.

Jonathan L. Halperin, M.D.

CHAPTERS - continued

- C-25. **Halperin JL**. Peripheral vascular disease. In *Essential Cardiology*, C. Rosendorff, ed. Philadelphia: WB Saunders 2000, pp 828-845.
- C-26. **Halperin JL**. Antithrombotic therapy for patients with peripheral arterial disease. In Hirsch AT (ed) Primary Care Series: Peripheral Arterial Disease and Intermittent Claudication. *An Office-Based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease*. Belle Mead, NJ, Excerpta Medica, Inc. 2001; pp 36-41.
- C-27. **Halperin JL** (editor). *An Office-Based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease* (Hirsch, AT, series editor). Part VIII: Peripheral Arterial Disease and Risk-factor Management. Excerpta Medica, Inc. 2001; pp. 177-202
- C-28. **Halperin JL**. Acute limb ischemia. In *Peripheral Arterial Disease: Diagnosis and Treatment*, J. D. Coffman and R. T. Eberhardt, eds. Totowa, NJ: Humana Press, Inc. 2002; pp. 119-144.
- C-29. Gombert-Maitland M, **Halperin JL**, Creager MA. Aortic and arterial aneurysms. In *Atlas of Heart Diseases*, 2nd edition, edited by MA Creager and E. Braunwald. Philadelphia: Current Medicine, Inc. 2002; pp. 1-23.
- C-30. **Halperin JL**. Anticoagulation in the Elderly. In *Cardiovascular Disease in the Elderly Patient*, edited by WS Aronow and Fleg. New York: Marcel Dekker, Inc. 2004; pp. 677-693.
- C-31. **Halperin JL**, Olin JW. Diseases of the Aorta. In Hurst's *The Heart*, 11th edition, edited by V Fuster, RW Alexander, RA O'Rourke, R Roberts, SB King and HJJ Wellens. New York: McGraw-Hill 2004.
- C-32. **Halperin JL**, Olin JW. Diagnosis and treatment of atherosclerotic diseases of the aorta. In *Atherothrombosis*, 2nd edition, edited by V Fuster, E Topol and E Nabel. Philadelphia: Lippincott Williams & Wilkins, 2005, pp 1497-1514.
- C-33. Jang JJ, **Halperin JL**. Peripheral vascular disease. In *Essential Cardiology*, 2nd edition, edited by C. Rosendorff. Philadelphia: WB Saunders 2005; pp 807-828.
- C-34. Darrow BJ, **Halperin JL**. Antithrombotic therapy for patients with atrial fibrillation. In *Hemostasis and Thrombosis*, 5th edition, edited by SZ Goldhaber. Philadelphia: Lippincott Williams & Wilkins 2006; pp. 1517-1528.

Jonathan L. Halperin, M.D.

CHAPTERS – continued

- C-35. Creager MA, Coffman JD, **Halperin JL**. Raynaud's Phenomenon. In *Vascular Medicine: A Companion to Braunwald's Heart Disease*, edited by MA Creager, VJ Dzau, J Loscalzo, W.B. Saunders 2006; pp 689-705.
- C-36. Shih AT, **Halperin JL**. Atrial Fibrillation and Hypertension. In *Advanced Therapy in Hypertension and Vascular Disease*, edited by ER Mohler III and RR Townsend. Hamilton, Ontario: B.C. Decker, Inc. 2006; pp 136-142.
- C-37. Elefteriades JA, Olin JW, **Halperin JL**. Diseases of the aorta. In Hurst's *The Heart*, 12th edition, edited by V Fuster, RW Alexander, RA O'Rourke, R Roberts, SB King and HJJ Wellens. New York: McGraw-Hill 2008, pp 2305-2328.
- C-38. Gornik, H, Gomberg-Maitland M, **Halperin JL**. Aortic and arterial aneurysms. In *Atlas of Heart Diseases*, 3rd edition, edited by MA Creager and E. Braunwald. Philadelphia: Current Medicine, Inc. 2008.
- C-39. Elefteriades, JA, Olin JW, **Halperin JL**. Diseases of the aorta. In Hurst's *The Heart*, 13th edition, edited by V Fuster, RW Alexander, RA O'Rourke, R Roberts, SB King and HJJ Wellens. New York: McGraw-Hill 2010, pp 2259-2289.
- C-40. Harburger J, **Halperin JL**. Cardiac involvement in Lyme disease. In *Lyme Disease: An evidence-based approach*. Edited by J Halperin, Oxfordshire, UK: CABI Books 2011 (in press).
- C-41. Bhasin K, **Halperin JL**. Atrial fibrillation and flutter. In *Handbook of Hospital Medicine*. Edited by A Dunn, N Kathuria and P Klotman. Singapore: World Scientific Press 2011 (in press).
- C-42. Kawano T, **Halperin JL**. Prevention of Thromboembolic Stroke in Patients with Atrial Fibrillation, Valvular Heart Disease or Cardiomyopathy. In Marder VJ, Aird WC, Bennett JS, Schulman S and White GC. *Hemostasis And Thrombosis: Basic Principles and Clinical Practice*, 6th edition. Ambler, PA: Wolters Kluwer - Lippincott Williams & Wilkins 2011 (submitted for publication).

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS

- G-1a. Fuster V, Rydén LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, **Halperin JL**, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). *Eur Heart J* 2001; 22:1852-923.
- G-1b. Fuster V, Rydén LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, **Halperin JL**, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). *J Am Coll Cardiol* 2001; 38: 1231-1266.
http://www.acc.org/clinical/guidelines/atrial_fib/pdfs/AFguideline8_30.pdf
- G-1c. Fuster V, Rydén LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, **Halperin JL**, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). *Circulation* 2001; 104:2118-50.
- G-2. Furie KL, Sacco RL, Broderick JP, Goldstein LB, Gorelick PB, **Halperin JL**, Hart RG, Howard G, Johnston SC, Kernan WN, Radziskewska B, Robertson RM, Smith DB, Wolf PA. Prevention of first and recurrent stroke. *Report of the Stroke Progress Review Group*. National Institute of Neurological Disorders and Stroke 2002; 75-8.
- G-3. Creager MA., Hirsch AT, Cooke JP, Olin JW, Jaff MR, Rooke T, **Halperin JL**. Working Group on Fellowship Training in Vascular Medicine: The Society for Vascular Medicine and Biology. Postgraduate training in vascular medicine: Proposed Requirements and Standards. *Vasc Med* 2003; 8:47-52.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS - continued

- G-4. McNamara RL, Brass LM, Drozda JP, Go AS, **Halperin JL**, Kerr CR, Levy S, Malenka DJ, Mittal S, Pelosi F, Rosenberg Y, Stryer D, Wyse DG. ACC/AHA Elements and data definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology Task Force on Clinical Data Standards (Atrial Fibrillation Clinical Data Standards Writing Committee). *Circulation* 2004;109:3223-3243. <http://www.acc.org/clinical/topic/topic.htm#datastandards>
- G-5. Singer DE, Albers GW, Dalen JE, Go AS, **Halperin JL**, Manning WJ. Long-term antithrombotic therapy for chronic atrial fibrillation or atrial flutter: Anticoagulants and antiplatelet agents. In Seventh ACCP Consensus Conference on Antithrombotic Therapy: Antithrombotic Therapy in Atrial Fibrillation. American College of Chest Physicians. *Chest* (Suppl) 2004; 126: 429S-456S.
- G-6a. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *J Am Coll Cardiol* 2004;44:E1-E211.
- G-6b. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). *Circulation* 2004; 110: e82-292.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

- G-7a. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *Circulation* 2004; 110:1168-76.
- G-7b. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM Jr, Lytle BW, Marlow RA, Nugent WC, Orszulak TA, Antman EM, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Ornato JP. American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American Society for Thoracic Surgery and the Society of Thoracic Surgeons. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). *J Am Coll Cardiol* 2004; 44:1146-54, e213-310.
- G-8. Guyatt G, Bauman M, Pauker S, **Halperin JL**, Carlin B, Owens D, Tosteson A, Gutterman D, Mauer J, Prins M, Zelman-Lewis S, Schunemann H. Consideration of resource allocation issues in clinical practice guidelines: Recommendations from an ACCP-sponsored task force. *Chest* 2006; 129: 182-187. (<http://www.chestjournal.org/cgi/content/full/129/1/182>)
- G-9a. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult -- Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *J Am Coll Cardiol* 2005; 46:1116-43.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-9b. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, **Halperin JL**, Hiratzka LF, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult -- Summary Article. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). *Circulation* 2005; 112: 1825-1852.
- G-10. Sacco RL, Adams R, Albers GW, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, **Halperin JL**, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack. Stroke Council of the American Heart Association. *Stroke* 2006; 37; 577-617.
(<http://stroke.ahajournals.org/cgi/content/full/37/2/577>)
- G-10a. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, **Halperin JL**, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. *Circulation* 2006; 14:e409-49.
- G-11. Creager MA, Jones DW, Easton JD, **Halperin JL**, Hirsch AT, Matsumoto AH, O'Gara PT, Safian RD, Schwartz GL, Spittell JA. American Heart Association Conference Proceedings Atherosclerotic Vascular Disease Conference: Writing Group V: Medical decision making and therapy. *Circulation* 2004; 109: 2634-2642.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-12a. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, **Halperin JL**, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A Collaborative Report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). American College of Cardiology Web Site. Available at: <http://www.acc.org/clinical/guidelines/pad/index.pdf>.
- G-12b. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, **Halperin JL**, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr., White CJ, White J, White RA. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease [Lower Extremity, Renal, Mesenteric, and Abdominal Aortic]). *J Am Coll Cardiol* 2006; 47:1239-312. Summary available at www.acc.org/clinical/guidelines/pad/summary.pdf.
- G-12c. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, **Halperin JL**, Hiratzka LF, Murphy WRC, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr., White CJ, White J, White RA. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease -- Summary of Recommendations. *J Vasc Interv Radiol* 2006; 17: 1383-98.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

- G-13. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, **Halperin JL**, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Available at: http://www.acc.org/clinical/guidelines/perio_betablocker.pdf.
- G-13a. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, **Halperin JL**, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 Guideline Update on Perioperative Cardiovascular Evaluation for Noncardiac Surgery: Focused Update on Perioperative Beta-Blocker Therapy. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *J Am Coll Cardiol* 2006; 47: 2343-2355.
- G-14a. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, ESC Committee for Practice Guidelines, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, ACC/AHA (Practice Guidelines) Task Force Members, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, **Halperin JL**, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Eur Heart Journal*. 2006; 27:1979-2030.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-14b. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, ESC Committee for Practice Guidelines, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, ACC/AHA (Practice Guidelines) Task Force Members, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, **Halperin JL**, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *J Am Coll Cardiol* 2006;48:854-906.
- G-14c. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey J-Y, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, ESC Committee for Practice Guidelines, Priori SG, Blanc J-J, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, ACC/AHA (Practice Guidelines) Task Force Members, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, **Halperin JL**, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Europace* 2006; 8: 651-745.
- G-14d. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey JY, Neal Kay G, Lowe JE, Bertil Olsson S, Prystowsky EN, Tamargo JL, Wann S. Guidelines for the management of patients with atrial fibrillation: Executive summary (text in Spanish). *Rev Esp Cardiol* 2006; 59:1329.
- G-14e. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey JY, Neal Kay G, Lowe JE, Bertil Olsson S, Prystowsky EN, Tamargo JL, Wann S. Guidelines for the management of patients with atrial fibrillation (text in Polish). *Kardiologia Pol* 2006; 64:1223-80.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

- G-14f. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, **Halperin JL**, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: Executive summary. *Rev Port Cardiol* 2007; 26:383-446. (text in Portuguese)
- G-15a. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *J Am Coll Cardiol* 2006; 48: e1-148.
<http://www.acc.org/clinical/guidelines/valvular/index.pdf>.
- G-15b. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation* 2006; 114:e84-231. Erratum in: *Circulation* 2007; 115:e409.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

G-16a. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. *J Am Coll Cardiol* 2006;48 1064-1108.

<http://content.onlinejacc.org/cgi/content/full/48/5/1064>

G-16b. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006; 114:e385-484.

G-16c. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death — Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. *Europace* 2006; 8:746-837.

G-16d. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, Gregoratos G, Klein G, Moss AJ, Myerburg RJ, Priori SG, Quinones MA, Roden DM, Silka MJ, Tracy C, Smith SC, Jacobs AK, Adams CD, Antman EM, Anderson JL, Hunt SA, **Halperin JL**, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JP, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, and Zamorano JL. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death — Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. *Eur Heart J* 2006; 27: 2099-140.

G-17a. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction-Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *J Am Coll Cardiol* 2007; 50: 652-726. (e1-e157).

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-17b. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE 2nd, Fesmire FM, Hochman JS, Levin TN, Lincoff AM, Peterson ED, Theroux P, Wenger NK, Wright RS, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction -- Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. *Circulation*. 2007; 116: e148-304.
- G-18a. Estes NAM, **Halperin JL**, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie J, Romeo SJW, Waldo AL, Wyse DG. ACC/AHA/Physician Consortium 2007 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: A report of the ACC/AHA Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Performance Measures for Atrial Fibrillation). *J Am Coll Cardiol* 2008; 51:865-884.
- G-18b. Estes NAM, **Halperin JL**, Calkins H, Ezekowitz MD, Gitman P, Go AS, McNamara RL, Messer JV, Ritchie J, Romeo SJW, Waldo AL, Wyse DG. ACC/AHA/Physician Consortium 2007 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: A report of the ACC/AHA Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Performance Measures for Atrial Fibrillation). *Circulation* 2008; 117:1101–1120.
- G-19. Singer DE, Albers GW, Dalen JE, Go AS, **Halperin JL**, Manning WJ, Lip GYK. Long-term antithrombotic therapy for chronic atrial fibrillation or atrial flutter: Anticoagulants and antiplatelet agents. In 8th ACCP Consensus Conference on Antithrombotic Therapy: Antithrombotic Therapy in Atrial Fibrillation. American College of Chest Physicians. *Chest* (Suppl) 2008; 133:546S-592S.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-20a. Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology; American Heart Association on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 guidelines for the management of patients with chronic stable angina. *J Am Coll Cardiol* 2007; 50:2264-74.
- G-20b. Fraker TD, Fihn SD, Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Tarkington LG, Yancy CW; American College of Cardiology; American Heart Association on behalf of the 2002 Chronic Stable Angina Writing Committee. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 guidelines for the management of patients with chronic stable angina. *Circulation*. 2007;116:2762_2772.
- G-21. Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, **Halperin JL**, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T, Sacco R. American Heart Association/American Stroke Association Council on Stroke; Council on Cardiovascular Radiology and Intervention; American Academy of Neurology. Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. *Stroke* 2008; 39:1647-1652.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-22. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, **Halperin JL**, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery); American Society of Echocardiography; American Society of Nuclear Cardiology; Heart Rhythm Society; Society of Cardiovascular Anesthesiologists; Society for Cardiovascular Angiography and Interventions; Society for Vascular Medicine and Biology; Society for Vascular Surgery. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). *Anesth Analg* 2008;106:685-712.
- G-23. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, **Halperin JL**, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2008; 27;51(21):e1-62.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-23a. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, **Halperin JL**, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Heart Rhythm* 2008; 5:934-55.
- G-23b. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, **Halperin JL**, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. *Circulation* 2008;117(21):e350-408.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

- G-24. Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, del Nido P, Fasules JW, Graham TP Jr, Hijazi ZM, Hunt SA, King ME, Landzberg MJ, Miner PD, Radford MJ, Walsh EP, Webb GD, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Page RL, Riegel B, Tarkington LG, Yancy CW. American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease); American Society of Echocardiography; Heart Rhythm Society; International Society for Adult Congenital Heart Disease; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2008;52:e1-121.
- G-25. Bairey Merz CN, Alberts MJ, Balady GJ, Ballantyne CM, Berra K, Black HR, Blumenthal RS, Davidson MH, Fazio SB, Ferdinand KC, Fine LJ, Fonseca V, Franklin BA, McBride PE, Mensah GA, Merli GJ, O’Gara PT, Thompson PD, Underberg JA, **Halperin JL**, Creager MA, Fung GL, Holmes DR, Nash IS, Newby LK, Piña I, Rodgers GP, Tracy CM, Weitz HH. ACCF/AHA/ACP 2009 competence and training statement: a curriculum on prevention of cardiovascular disease: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Competence and Training (Writing Committee to Develop a Competence and Training Statement on Prevention of Cardiovascular Disease). *J Am Coll Cardiol* 2009; 54: 1336–63.
- G-26. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine (developed in collaboration with the American College of Emergency Physicians). *J Am Coll Cardiol* 2010; 55: e27–129.

Jonathan L. Halperin, M.D.**GUIDELINES and POSITION STATEMENTS – continued**

- G-26a. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, Eagle KA, Hermann LK, Isselbacher EM, Kazerooni EA, Kouchoukos NT, Lytle BW, Milewicz DM, Reich DL, Sen S, Shinn JA, Svensson LG, Williams DM, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine (developed in collaboration with the American College of Emergency Physicians). *Circulation* 2010; 121: e266-369.
- G-27. Francis GS, Greenberg BH, Hsu DT, Jaski BE, Jessup M, LeWinter MM, Pagani FD, Piña IL, Semigran MJ, Walsh MN, Wiener DH, Yancy CW Jr., **Halperin JL**, Creager MA, Fung GL, Holmes DR, Merli G, Nash IS, Newby LK, Weitz HH. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. *J Am Coll Cardiol* 2010; 56: 424-453.
- G-28. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, **Halperin JL**, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. AHA/ASA Scientific Statement: Guidelines for the Prevention of Stroke in Patients with Stroke and Transient Ischemic Attack. *Stroke* 2011; 42:227-276 (published online October 21, 2010).
- G-29. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JMcB, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor, AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010; 56: 2182-2199, e50-103.

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-29a. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JMcB, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Taylor, AJ, Weintraub WS, Wenger NK, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy CW. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2010; (in press).
- G-30. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy on behalf of the 2011 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS Focused Update for the Management of Patients With Atrial Fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* 2011; 123:104-123 (published online Dec 20, 2010).
- G-30a. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy on behalf of the 2011 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS Focused Update for the Management of Patients With Atrial Fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2011; 57:223-42 (published online Dec 20, 2010).

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

- G-30b. Wann LS, Curtis AB, Ellenbogen KA, Estes NAM, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Jacobs AK, Smith SC, Anderson JL, Adams CD, Buller CE, Creager MA, Ettinger SM, Guyton RA, **Halperin JL**, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura R, Page RL, Riegel B, Stevenson WG, Tarkington LG, Yancy on behalf of the 2011 ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation Writing Committee. 2011 ACCF/AHA/HRS Focused Update for the Management of Patients With Atrial Fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Heart Rhythm* 2011; (in press).
- G-31a. Brott TG, **Halperin JL**, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ. 2011ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/-SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *Circulation* 2011;123 (in press).
- G-31b. Brott TG, **Halperin JL**, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ. 2011ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/-SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *J Am Coll Cardiol* 2011;27 (in press; published online January 31, 2011).

Jonathan L. Halperin, M.D.

GUIDELINES and POSITION STATEMENTS – continued

G-31c. Brott TG, **Halperin JL**, Abbara S, Bacharach JM, Barr JD, Bush RL, Cates CU, Creager MA, Fowler SB, Friday G, Hertzberg VS, McIff EB, Moore WS, Panagos PD, Riles TS, Rosenwasser RH, Taylor AJ. 2011ASA/ACCF/AHA/AANN/AANS/ACR/CNS/SAIP/-SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. *Stroke* 2011; (in press).

APPEARS THIS WAY ON ORIGINAL

Jonathan L. Halperin, M.D.

MONOGRAPHS and SUPPLEMENTS

- M-1. **Halperin JL** (editor). *An Office-Based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease* (Hirsch, AT, series editor). Part VIII: Peripheral Arterial Disease and Risk-factor Management. Excerpta Medica, Inc. 2001; suppl.
- M-2. **Halperin JL**. On the horizon: Advances in the prevention of stroke in atrial fibrillation. In *The Rhythm of Life—Management of Atrial Fibrillation: New Anticoagulant and Antiarrhythmic Strategies* (Halperin, JL, editor) *Today in Cardiology*, March 2002.
- M-3. **Halperin JL**. An oral direct thrombin inhibitor for the prevention and treatment of thromboembolism. In *New Approaches to Antithrombotic Therapy* (Weitz JI, Ansell JE, **Halperin JL** and Hambleton J, editors). Institute for Continuing Healthcare Education, 2002.
- M-4. Fuster V, Rydén LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, **Halperin JL**, Kay GN, Klein WW, Lévy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC Pocket guidelines: *Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation)*. American College of Cardiology, 2002.
- M-5. Kearon C (editor). *Venous Thromboembolism* (Jaff MR, **Halperin JL**, series editors). Part I: Epidemiology, Risk Factors and Natural History. *Circulation* 2003; 107 [suppl I]:I-1 - 30.
- M-6. Moneta G. (editor). *Venous Thromboembolism* (Jaff MR, **Halperin JL**, series editors). Part II: Diagnosis of Venous Thromboembolism. *Circulation* 2004; 109 [suppl]: I-1-27.
- M-7. Weitz J. (editor). *Venous Thromboembolism* (Jaff MR, **Halperin JL**, series editors). Part III: Treatment of Venous Thromboembolism. *Circulation* 2004; 110 [suppl]: I-1-27.
- M-8. Goldhaber SZ. (editor). *Venous Thromboembolism* (Jaff MR, **Halperin JL**, series editors). Part IV: Prevention of Venous Thromboembolism. *Circulation* 2004; 110 [suppl] IV-1-33.
- M-9. Hirsh J, **Halperin JL** (editors). *A Clinician's Guide to Thrombosis*. American Heart Association and American Stroke Association. Shaw Science (text and CD-ROM) 2005.

Jonathan L. Halperin, M.D.

INVITED ARTICLES:

- I-1. **Halperin JL**, Coffman JD. Pathophysiology of Raynaud's disease. *Arch Intern Med* 1979; 129: 89-92.
- I-2. **Halperin JL**. Peripheral vasospastic diseases: current pharmacological therapy. *Primary Cardiology* 1983; 9:Suppl 2, 110-116.
- I-3. **Halperin JL**. Drug therapy of cold sensitivity. *Vasc Diag & Ther* 1983; 4:21-25.
- I-4. **Halperin JL**. Alpha-adrenergic inhibitor drugs and Raynaud's phenomenon. *Aspects of Hypertension*, 1984.
- I-5. Faxon DP, Creager MA, **Halperin JL**, Bernard DB, Ryan TJ. Redistribution of regional blood flow following angiotensin converting enzyme inhibitors: comparison of normal subjects and patients with heart failure. *Am J Med* 1984; 76:Suppl 5B, 104-110.
- I-6. Packer M, **Halperin JL**, Brooks KM, Rothlauf EB, Lee WH. Nitroglycerin therapy in the management of pulmonary hypertensive disorders. *Am J Med* 1984; 77:Suppl, 67-75.
- I-7. **Halperin JL**. Coming to grips with claudication. *Acute Care Med* 1985; 2:12-20.
- I-8. **Halperin JL**. The role of angiotensin inhibitors in congestive heart failure. *Primary Cardiology* 1985; 11:111-124.
- I-9. **Halperin JL**, Levine R. The high cost of heart bypass. *Science Digest* 1985; 93:60-63.
- I-10. **Halperin JL**, Rothlauf EB. The new pacemakers. *Primary Cardiology* 1986; 12:12-31.
- I-11. **Halperin JL**. Peripheral vascular disease: medical evaluation and treatment. *Geriatrics* 1987; 42:47-61.
- I-12. Stein B, Fuster V, **Halperin JL**, Chesebro JH. Antithrombotic therapy in cardiac disease: An emerging approach based on pathogenesis and risk. *Circulation* 1989; 80:1501-1513.
- I-13. Sherman W, **Halperin JL**. Unstable Angina: Coronary Angioplasty and Bypass Surgery. *Curr Opin Cardiol* 1989; 4:505-509.
- I-14. Fuster V, Stein B, **Halperin JL**, Chesebro JH. Antithrombotic therapy in cardiac disease. *Am J Cardiol* 1990; 65:38C-44C.

Jonathan L. Halperin, M.D.

INVITED ARTICLES - continued

- I-15. Stein B, **Halperin JL**, Fuster V. Prevention of left ventricular mural thrombosis and embolism during and after acute myocardial infarction. *Coronary Artery Disease* 1990; 1:180-189.
- I-16. **Halperin JL**. Prevention of deep venous thrombosis and pulmonary embolism in surgical patients. *Mt Sinai J Med* 1990; 58:28-33.
- I-17. Kukin M, **Halperin JL**. Acute myocardial infarction: special care units, analgesia and complications. *Curr Opin Cardiol* 1990; 5:.
- I-18. **Halperin JL**. Prevention of embolism in atrial fibrillation. *Vasc Med Rev* 1991; 2:111-119.
- I-19. Flaker GC, McBride R, Blackshear JL, Kronmal RA, **Halperin JL**, Hart RG. Weighing risk versus benefit of antiarrhythmic drug therapy for atrial fibrillation. *Cardiol Board Rev* 1993; 10:28-37.
- I-20. **Halperin JL**, Rothlauf EB. Stroke Prevention in atrial fibrillation. *Mt Sinai J Med* 1993; 60:289-294.
- I-21. **Halperin JL**. Thrombosis in the left ventricle in patients with dilated cardiomyopathy. *G Ital Cardiol* 1994; 24:281-289.
- I-22. Chesebro JH, **Halperin JL**, Fuster V. Non-valvular atrial fibrillation: a risk marker for stroke of cardiac and vascular origin. In *Atrial Arrhythmias: State of the Art*, edited by JP DiMarco and EN Prystowsky. Armonk, NY: Futura Publishing Company, Inc. American Heart Association Monograph Series, 1995, pp 97-104.
- I-23. Fuster V, **Halperin JL**. Aortic dissection: a medical perspective. *J Card Surg* 1994; 9:713-728.
- I-24. **Halperin JL**. First Person: New ways to prevent stroke in atrial fibrillation. *Cardio* Sept 1994; 54.
- I-25. **Halperin JL**. Coronary artery disease and peripheral vascular disease: Unravelling the links. *Cardiol Rev* 1996; 4:1, 25-33.

Jonathan L. Halperin, M.D.

INVITED ARTICLES - continued

- I-26. Flaker GC, Fletcher KA, Rothbart RM, **Halperin JL**, Hart RG. Clinical and echocardiographic features predicting recurrent atrial fibrillation. *Cardiol Board Rev* 1996; 13:26-28.
- I-27. Pullicino, P,**Halperin JL**, Thompson JLP. Stroke in patients with heart failure and reduced ejection fraction: *Neurology* 2000;54:288.
- I-28. **Halperin JL**. Antithrombotic therapy for patients with peripheral arterial disease. In Hirsch AT and Creager MA (eds) *Am J Med* Continuing Education Series. An Office-Based Approach to the Diagnosis and Treatment of Peripheral Arterial Disease. Part II: Recognizing and Treating Systemic Atherosclerosis. Excerpta Medica, Inc. 1998; suppl; pp. 8-13.
- I-29. **Halperin JL**. Anticoagulants in atrial fibrillation: A guide to best use. *Consultant*. 2000; 40: 422-30).
- I-30. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS,**Halperin JL**, Raschke R, Granger C, Ohman EM and Dalen JE. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Sixth ACCP Consensus Conference on Antithrombotic Therapy. *Chest* 2001; 119 (Suppl): 64S-94S.
- I-31. Hirsh J, Anand SS, **Halperin JL**, Fuster V. Guide to anticoagulant therapy: Heparin *Circulation* 2001; 103:2994-3018.
- I-32. Hirsh J, Fuster V, Ansell J,**Halperin, JL**. American Heart Association/American College of Cardiology Foundation: Guide to warfarin therapy. *Circulation* 2003; 107:1692-1711.
- I-32a. Hirsh J, Fuster V, Ansell J,**Halperin, JL**. American Heart Association/American College of Cardiology Foundation: Guide to warfarin therapy. *J Am Coll Cardiol* 2003; 41:1633-52.
- I-33. **Halperin JL**. Ten most commonly asked questions about stroke prevention in atrial fibrillation. *Cardiology in Review*. 2001; 9:187-192.
- I-34. **Halperin JL**. Antithrombotic therapy for atrial fibrillation: Balancing the risks. *Cardiovascular Reviews & Reports* 2002; 23:52-57.
- I-35. **Halperin JL**. Evaluation of patients with peripheral vascular disease. *Thromb Res* 2002; 106: V303-311.

Jonathan L. Halperin, M.D.

INVITED ARTICLES - continued

- I-36. **Halperin, JL.** Expanding the value of oral anticoagulation in the geriatric population: A focus on stroke prevention in atrial fibrillation. *Clin Geriatr (Suppl)* 2001; <http://www.iche.edu/9-01cgssuppl/901cgssuppl.pdf>.
- I-37. Gombert-Maitland M, **Halperin JL.** Use of IIb/IIIa inhibitors in patients with acute coronary syndromes who do not undergo percutaneous coronary intervention. *ACC Curr J Rev* 2002; 11:65-68.
- I-38. **Halperin JL.** Antithrombotic therapy in atrial fibrillation – ximelagatran, an oral direct thrombin inhibitor. *Expert Review of Cardiovascular Therapy.* 2004; 2:163-74.
- I-39. **Halperin JL.** Overview of ximelagatran in worldwide clinical trials. *Today's Therapeutic Trends* 2004; 22(1): 43-68.
- I-40. **Halperin JL.** Anticoagulation for atrial fibrillation in the elderly. *Am J Geriatr Cardiol* 2005; 14:81-86.
- I-41. **Halperin JL.** State-of-the-art review: Oral anticoagulant therapy in atrial fibrillation: The emerging role of direct thrombin inhibition. *J Am Coll Cardiol* 2005; 45:1-9. <http://authors.elsevier.com/sd/article/S0735109704019424>
- I-42 **Olsson SB, Halperin JL.** Prevention of stroke in patients with atrial fibrillation. *Semin Vasc Med* 2005; 5: 285-292.
- I-43. Nair A, Sealove B, **Halperin JL,** Webber G, Fuster V. Anticoagulation in patients with heart failure: Who, when and why? *Eur Heart J* 2006; 27 (Suppl).
- I-44. **Halperin JL.** Atrial fibrillation: You can have it and not know it. *Bottom Line: Retirement.* 2006; 14: (October); 3-5.
- I-45. Jawetz, S, **Halperin, JL.** Prevention of stroke in patients with atrial fibrillation: Challenges to alignment of anticoagulation guidelines in the East and West. *Int Rev Thromb* 2007; 1:57-64.
- I-46. Strong SH, **Halperin JL.** Confronting atrial fibrillation in the elderly: Stroke risk stratification and emerging antithrombotic approaches. *Geriatrics* 2007; 62:22-27.

Jonathan L. Halperin, M.D.

INVITED ARTICLES – continued

- I-47. Büller HR, **Halperin JL**, Bounameaux H, Prins M. Double-blind studies are not always optimum for evaluation of a novel therapy: The case of new anticoagulants. *J Thromb Haemost* 2008; 6:227-9. E-published November 22, 2007.
DOI:10.1111/j.1538-7836.2007.02848.x.
- I-48. Reynolds DA, **Halperin JL**. Anticoagulation in women with non-valvular atrial fibrillation: Insights from clinical trials. *Women's Health* 2007; 3:673-678.
- I-49. Hohnloser SH, Duray GZ, Baber U, **Halperin JL**. Prevention of stroke in patients with atrial fibrillation: Current strategies and future directions. *Eur Heart J* 2008; *Suppl* 2008; H4-10.
- I-50. Rubboli A, **Halperin, JL**. Warfarin, aspirin and clopidogrel is the recommended antithrombotic regimen for anticoagulated patients who present with acute coronary syndromes and/or undergo percutaneous coronary interventions. *Thromb Haemost* 2008;100:752-3.
- I-51. **Halperin JL**. What can ongoing clinical trials of anticoagulants demonstrate? *J Cardiovas Med (Hagerstown)* 2009; 1:1-12 (published online June 23, 2009).
- I-52. Broukhim M, **Halperin JL**. Stroke prevention in the high risk patient with atrial fibrillation: Medical management. *Curr Cardiol Rep* 2011; 13:9-17 (published online October 15, 2010).

Jonathan L. Halperin, M.D.

EDITORIALS:

- E-1. **Halperin JL**, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. *Stroke* 1988; 19:937-941.
- E-2. Fuster V, **Halperin JL**. Left ventricular thrombi and cerebral embolism: an emerging approach. *N Engl J Med* 1989; 320:392-394.
- E-3. **Halperin JL**. Aspirin for primary prevention of cardiovascular disease. *Mgmt Options Cardiol* 1989; 1:4-5.
- E-4. **Halperin JL**, Fuster V. Left ventricular thrombus and stroke after myocardial infarction: toward prevention on perplexity? *J Am Coll Cardiol* 1989; 14:912-914.
- E-5. Fuster V, Cohen M, **Halperin JL**. Aspirin in the prevention of coronary disease. *N Engl J Med* 1989; 321:183-185.
- E-6. Chesebro JH, Fuster V, **Halperin JL**. Atrial Fibrillation: risk marker for stroke. *N Engl J Med* 1990; 323:1556-1558.
- E-7. **Halperin JL**, Hart RG. Mr. Bush's stroke outlook. *Medical Tribune* 1991; 32:7, (May 30).
- E-8. Rosenthal MS, **Halperin JL**. Thromboembolism in nonvalvular atrial fibrillation: the answer may be in the ventricle. *Int J Cardiol* 1992; 37:277-282.
- E-9. Hart RG, **Halperin JL**. Atrial fibrillation and Stroke: revisiting the dilemmas. *Stroke* 1994; 25: 1337-1341.
- E-10. Fuster V, Hart, RG, **Halperin JL**. Anticoagulation to prevent stroke: Defining the problems and risk stratification. In *Atrial Arrhythmias: State of the Art*, edited by JP DiMarco and EN Prystowsky. Armonk, NY: Futura Publishing Company, Inc. American Heart Association Monograph Series, 1995, pp 327-332.
- E-12. Hart RG, **Halperin JL**. Atrial fibrillation and stroke: Concepts and controversies. *Stroke* 2001; 32:803-808.

Jonathan L. Halperin, M.D.

EDITORIALS - continued

- E-13. Hirsh J, Anand SS, **Halperin JL**, Fuster V. Mechanism of action and pharmacology of unfractionated heparin. *Arterioscler Thromb Vasc Biol* 200; 21: 1094-6.
- E-14. **Halperin JL**, Fuster V. Patent foramen ovale and recurrent stroke: Another paradoxical twist. *Circulation* 2002; 105:2580-2582.
- E-15. **Halperin JL**, Fuster V. Meeting the challenge of peripheral arterial disease. *Arch Intern Med* 2003; 163:877-8.
- E-16. **Halperin JL**, Gomberg-Maitland M. Obliteration of the left atrial appendage for prevention of thromboembolism. *J Am Coll Cardiol* 2003; 42: 1259-61.
- E-17. Pullicino P, **Halperin JL**. Combining carotid endarterectomy with coronary bypass surgery: Is it worth the risk? *Neurology* 2005; 64:1332–1333.
- E-18. Freudenberger RS, **Halperin JL**. Anticoagulation for patients with chronic heart failure: Science or religion? *Nature Clin Prac Cardiovasc Med* 2006; 3: 580-581.
- E-19. Cohen RA, **Halperin JL**, Creager MA, Eberhardt RT. In Memoriam: Jay D. Coffman, M.D. 1928-2006. *Circulation* 2007; 115:2876-2877.
(<http://circ.ahajournals.org/cgi/content/full/115/22/2876>)
- E-20. Creager MA, **Halperin JL**. In Memoriam: Jay Denton Coffman, M.D. 1928-2006. *Vasc Med* 2007; 12:221-2.
- E-21. Francescone S, **Halperin JL**. “Triple therapy” or triple threat? Balancing the risks of antithrombotic therapy for patients with atrial fibrillation and coronary stents. *J Am Coll Cardiol* 2008; 51: 826-7.
- E-22. **Halperin JL**. Heparin-induced thrombocytopenia and thrombosis. Practice Point Commentary. *Nature Clin Prac Cardiovasc Med* 2008; 5::440-441. E-published 2008 Jun 17, 2008. (PMID: 18560407)
- E-23. Hart RG, **Halperin JL**. Do current guidelines result in overuse of anticoagulation in patients with atrial fibrillation? *Ann Intern Med* 2009; 151: 355-356.
- E-24. Viles-Gonzalez, JF, **Halperin JL**. Everything counts in small amounts: Device-detected atrial high-rate arrhythmias. *Circ Arrhythm Electrophysiol* 2009; 2: 471-473.

Jonathan L. Halperin, M.D.

EDITORIALS - continued

- E-25. van der Zee, SA, **Halperin JL**. Warfarin sensitivity genotyping: Closer to clinical practice. *Nature Rev Cardiol* 2010; 7:549-550.
- E-26. Goldenberg NA, Spyropoulos AC, **Halperin JL**, Kessler CM, Schulman S, Turpie AGG, Skene AM, Cutler NR, Hiatt WR. Improving academic leadership and oversight in large industry-sponsored clinical trials: The ARO-CRO model. *Blood* 2010; (in press) prepublished online Nov 10, 2010; doi:10.1182/blood-2010-09-308858.
- E-27. Lip GYH, **Halperin JL**, Tse H-F. The new 2010 European Society of Cardiology guidelines on atrial fibrillation management: Evolution or revolution? *Chest* 2010; (in press).

APPEARS THIS WAY ON ORIGINAL

Jonathan L. Halperin, M.D.

ABSTRACTS:

- A-1. Quesenberry P, **Halperin JL**, Ryan M, Stohlman F. The role of endotoxin in colony-stimulating factor (CSF) elevations seen after irradiation. *Blood* 1972; 40: 949.
- A-2. Creager MA, **Halperin JL**, Klein MD, Coffman JD. Effects of acetylstrophanthidin on peripheral and central hemodynamics in acute myocardial infarction. *Clin Res* 1978; 26: 225A.
- A-3. **Halperin JL**, Coffman JD. Vasodilatation during mental stress in Raynaud's disease. *Circulation* 1978; 58:Suppl II, No. 8 (presented at American Heart Association 51st Scientific Sessions, Dallas, Texas, November 1978).
- A-4. Creager MA, Faxon DP, **Halperin JL**, Gavras H, Coffman JD, Ryan TJ. Effects of angiotensin inhibition on central and peripheral hemodynamics in congestive heart failure. *Clin Res* 1979; 27:160A.
- A-5. **Halperin JL**, Creager MA, Faxon DP, Gavras H, Ryan TJ. Chronic oral angiotensin inhibition for the treatment of refractory heart failure. *Circulation* 1979; 60:Part II, No. 4 (presented at American Heart Association 52nd Scientific Sessions, Anaheim, California, November 1979).
- A-6. Creager MA, **Halperin JL**, Faxon DP, Bernard DB, Ryan TJ. Regional blood flow during captopril therapy for heart failure. *Clin Res* 1980; 28:163A (presented at the National Meeting of the American Federation for Clinical Research, Washington, D.C., May 1980).
- A-7. Creager MA, **Halperin JL**, Bernard DB, Faxon DP, Ryan TJ. Reversal of sodium retention in heart failure by converting enzyme inhibition. *Clin Res* 1980; 28:538.
- A-8. Brodsky SJ, **Halperin JL**, Klein MD, Ryan TJ. Intravenous nitroglycerin infusion in unstable angina. *Clin Res* 1980; 28: 608A.
- A-9. Bass TA, Faxon DP, **Halperin JL**, Melidossian CD, McCabe CH, Ryan TJ. Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure. *Clin Res* 1981; 29:176A (presented at the National Meeting of American Federation for Clinical Research, San Francisco, California, April 1981).

Jonathan L. Halperin, M.D.

ABSTRACTS - continued

- A-10. Creager MA, Faxon DP, **Halperin JL**, Melidossian CD, McCabe CH, Ryan TJ. Determinants of survival and clinical response to captopril in patients with congestive heart failure. *Am J Cardiol* 1982; 49:988 (presented at the 31st Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, April 1982).
- A-11. Brooks KM, **Halperin JL**, Ambrose JA, Mindich BP, Gorlin R. Effects of nitroglycerin on pulmonary venous gradient in patients with mitral valve disease. *Clin Res* 1983; 31:71A.
- A-12. Estioko M, Camunas J, **Halperin JL**, Rothlauf E, Steinmetz M, Teichholz L. Pulsed-Doppler echocardiographic assessment of hemodynamic function during dual-chamber cardiac pacing. Proc VII World Symposium Cardiac Pacing. *PACE* 1983; 6: A-86 (presented at the Symposium in Vienna, Austria, May 1983).
- A-13. Machac J, Horowitz S, **Halperin JL**, Goldsmith S. Four-chamber timing analysis in patients with programmable A-V sequential pacemakers using multiharmonic Fourier analysis of gated images. *J Nuclear Med* 1983; 24:92 (presented at the Society of Nuclear Medicine 30th Annual Meeting, St. Louis, Missouri, June 1983).
- A-14. Brooks KM, **Halperin JL**, Rothlauf EB, Ambrose JA, Mindich BP, Teichholz LE. Effect of nitroglycerin on the pulmonary venous gradient in patients with mitral valve disease. *Circulation* 1983; 68:(Suppl) 343 (presented at the American Heart Association 56th Scientific Sessions, Anaheim, California, November 1983).
- A-15. **Halperin JL**, Rothlauf EB, Stern EH, Camunas JL, Estioko MR, Steinmetz MY, Teichholz LE. Pulsed-Doppler echocardiographic assessment of hemodynamic function during dual-chamber cardiac pacing. *Circulation* 1983; 68: (Suppl) 379 (presented at the American Heart Association 56th Scientific Sessions, Anaheim, California, November 1983).
- A-16. **Halperin JL**, Rothlauf EB, Mindich BP, Reder BF, Litwak RS, Kupersmith J. Limb hemodynamic effects of labetalol following coronary bypass surgery. *Clin Res* 1984; 32: 173A.
- A-17. Teichholz LE, Estioko MR, Camunas JL, Stern EH, Goldman ME, Steinmetz MY, Squire A, Shiang H, Rothlauf EB, **Halperin JL**. Peak aortic flow velocity for rapid evaluation of cardiac performance during physiological pacing. *Clin Res* 1984; 32: 173A.

Jonathan L. Halperin, M.D.

ABSTRACTS - continued

- A-18. **Halperin JL**, Camunas JL, Estioko MR, Rothlauf EB, Kupersmith J, Stern EH, Steinmetz MY, Teichholz LE. Tachycardia related to myopotential interference during atrial synchronous cardiac pacing: role of telemetered atrial electrograms. *Clin Res* 1984; 32:173A.
- A-19. **Halperin JL**, Teichholz LE, Steinmetz MY, Rothlauf EB, Camunas JL, Estioko MR. Selection of patients for dual-chamber pacing by noninvasive means: the VVI-variance index. *Circulation* 1984; 70: (Suppl II) 409 (presented at the American Heart Association 57th Scientific Sessions, Miami, Florida, November 1984).
- A-20. Mindich BP, **Halperin JL**, Rothlauf EB, Cohen M, Goldman ME, Guarino T. Effect of collateral filling on myocardial perfusion pressure in patients with coronary artery disease. *Clin Res* 1985; 33: (presented at the National Meeting of the American Federation for Clinical Research, Washington, D.C., May 1985).
- A-21. Goldman ME, Guarino T, **Halperin JL**, Mindich BP. Comparison of intra-operative contrast and Doppler echocardiography for evaluating valvular regurgitation. *Clin Res* 1985; 33: (presented at the National Meeting of the American Federation for Clinical Research, Washington, D.C., May 1985).
- A-22. Stern A, Rothlauf EB, **Halperin JL**. Acute limb hyperemic response to pentoxifylline in patients with intermittent claudication. *Clin Res* 1985; 33:749A.
- A-23. **Halperin JL**, Rothlauf EB, Mindich BP, Brooks KM, Ambrose JA. Effect of nitroglycerin during hemodynamic estimation of valve orifice in patients with mitral stenosis. *J Am Coll Cardiol* 1986; 7:169A (presented at the 35th Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 1986).
- A-24. **Halperin JL**, Rothlauf EB, Stern A. Potential adverse effect of pentoxifylline on limb hemodynamics in patients with intermittent claudication. *J Am Coll Cardiol* 1986; 7:177A (presented at the 35th Annual Scientific Sessions of the American College of Cardiology, Atlanta, Georgia, March 1986).
- A-25. Weinberger JM, Matarese EL, Rothlauf EB, **Halperin JL**. Carotid evaluation in patients with atrial fibrillation and cerebral ischemic symptoms. *Circulation* 1987; 76:(Suppl) 567A (presented at the American Heart Association 60th Annual Scientific Sessions, Anaheim, California, November 1987).

Jonathan L. Halperin, M.D.

ABSTRACTS - continued

- A-26. Gottlieb SS, **Halperin JL**, Kessler PD, Rothlauf EB, Packer M. Dissociation of the systemic and regional vascular responses to the vasodilator drug, flosequinan, in heart failure. *Circulation* 1987; 76: (Suppl) 1771A (presented at the American Heart Association 60th Scientific Sessions, Anaheim, California, November 1987).
- A-27. Machac J, Vallabhajosula S, Goldsmith SJ, Palestro C, Maksoud JL, **Halperin JL**, Einhorn TA, Aledort LA. Accuracy of In-111 platelet imaging of deep vein thrombosis following hip surgery. *J Nucl Med* 1988 (presented at the Society of Nuclear Medicine 35th Annual Meeting, New Orleans, Louisiana, June 1988).
- A-28. Stroke Prevention in Atrial Fibrillation Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study (presented at the American College of Cardiology 39th Annual Scientific Sessions, New Orleans, Louisiana, March 1990.)
- A-29. **Halperin JL**, Hart RG, McBride R, Kronmal R. Predictors of thromboembolism in atrial fibrillation. *Circulation* 1991;84: (Suppl). (Presented at the 64th Annual Scientific Sessions, of the American Heart Association, Anaheim, California, November 1991).
- A-30. **Halperin JL**. Meta-analysis of antithrombotic trials for atrial fibrillation. (Presented at the Plenary Session of the American Heart Association 64th Annual Scientific Sessions, Anaheim, California, November 1991).
- A-31. Flaker GC, Blackshear JL, McBride R, **Halperin JL**, Hart RG and the SPAF investigators. Antiarrhythmic drug therapy and cardiac mortality in the Stroke Prevention in Atrial Fibrillation study. *J Am Coll Cardiol* 1992; (Suppl III) 227A (presented at the 41st annual Scientific Sessions of the American College of Cardiology, Dallas, Texas, April 1992).
- A-32. **Halperin JL**. Stroke Prevention in Atrial Fibrillation (SPAF) II: Efficacy of warfarin vs. aspirin. (presented at the Plenary Session of the American College of Cardiology, 42nd Annual Scientific Session, Anaheim, California, March 1993).
- A-33. Fuster V, **Halperin JL**. Antithrombotic therapy for atrial fibrillation (presented at the European Congress of Cardiology, Nice, France, 1994).
- A-34. O'Gara, P, Harrington R, Langer A, **Halperin JL**, Fisher M, Feyzi J, Fuster V for the CARS Investigators. Coumadin® Aspirin Re-infarction Study (CARS): Relationship between event rates and INR. *Circulation* 1996; 93:Suppl I-80 (presented at the 69th Scientific Sessions of the American Heart Association, New Orleans, Louisiana, November 1996).

Jonathan L. Halperin, M.D.

ABSTRACTS - continued

- A-35. **Halperin JL** and Hart RG. Current recommendations for stroke prevention in atrial fibrillation: Where do we go from here? *Proceedings* p. 18. (Presented at the IVth International Symposium on Heart-Brain Interactions, Bologna, Italy, October 1996).
- A-36. Safford, RE, Chan K-L, Blackshear JL, **Halperin JL**, Asinger RW, Goldman ME, Zabalgoitia M, Koehler J. Transesophageal echocardiographic (TEE) correlates of thromboembolism in high-risk patients with atrial fibrillation treated with standard warfarin or low dose warfarin-aspirin combination therapy. *Cardiovasc Drugs Ther* 1997; 11 (suppl 2):403. (Presented at the 7th International Symposium on Cardiovascular Pharmacotherapy, Jerusalem, Israel, June, 1997).
- A-37. Vorchheimer D, Saffra N, Feyzi J, **Halperin JL**, DePeralta E, Guzman I, Califf R, Fuster V for the CARS Investigators. Temporal trends in medical therapy after acute myocardial infarction: U.S. and Canadian experience in the Coumadin Aspirin Reinfarction Study (CARS). *Cardiovasc Drugs Ther* 1997; 11(suppl 2):400.
- A-38. **Halperin JL** for the Stroke Prevention in Atrial Fibrillation Investigators. Aspirin for stroke prevention in atrial fibrillation: Prospective identification of atrial fibrillation patients at low risk of stroke during treatment with aspirin: The SPAF-III Aspirin Low-Risk Cohort Study. *Circulation* 1997; 96 (suppl 1):I-281 (presented at the 70th Scientific Sessions, of the American Heart Association, Orlando, FL, November 1997).
- A-39. Shimbo D, Geer E, Child J, Dronge A, Farkouh M, Reddy S, **Halperin JL**. The selective serotonin re-uptake inhibitor paroxetine inhibits endothelial-dependent vasodilatation. *J Am Coll Cardiol* 2000; 35:271A (presented at the 49th Annual Scientific Sessions of the American College of Cardiology, Anaheim, CA, March 2000).
- A-40. **Halperin JL**. Transesophageal echocardiography is most useful for the identification of high risk patients with atrial fibrillation: The SPAF-III study. *Proceedings* p. 17. (Presented at the Vth International Symposium on Heart-Brain Interactions, Bologna, Italy, October 1999).
- A-41. Dunn AS, Schechter CB, **Halperin JL**, Latzman, B. A mathematical model to predict maintenance warfarin dose adjustments. 2000; (presented at the regional and national annual meetings of the Society of General Internal Medicine).

Jonathan L. Halperin, M.D.

ABSTRACTS – continued

- A-42. Klein AL, Grimm RA, Murray D, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, **Halperin JL**, Orsinelli DA, Porter TR, Stoddard MF for the ACUTE Investigators. Six-month follow-up of patients undergoing a transesophageal echocardiography guided cardioversion from atrial fibrillation: The ACUTE trial. *Circulation* 2001 suppl. Presented at the Annual Scientific Sessions of the American Heart Association, Anaheim, CA, November 2001.
- A-43. Farkouh ME, Robbins MJ, Zafar MU, Shimbo D, **Halperin JL**, Davidson K, Volate R, Epstein EM, Patel M, Talor Z, Chesebro JH. Is there a role for troponin-I in the risk stratification of stable asymptomatic hemodialysis patients? *J Am Coll Cardiol* 2002; 39 (suppl): 456A-457A. Presented at the 51st Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 2002.
- A-44. **Halperin JL** on behalf of the SPORTIF-III Investigators. SPORTIF III: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. 2003; presented at the 52nd Annual Scientific Sessions of the American College of Cardiology, Chicago, IL, April 2, 2003. Late-breaking clinical trials III (online) <http://www.acc03online.acc.org/>.
- A-45. **Halperin JL** on behalf of the SPORTIF-V Investigators. SPORTIF V: A long-term randomized trial comparing ximelagatran with warfarin for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. *Circulation* 2003; 108: 2723, presented at the Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 11, 2003.
- A-46. **Halperin JL** for The Executive Steering Committee on Behalf of the SPORTIF Investigators. Efficacy and safety of ximelagatran compared with warfarin in women with nonvalvular atrial fibrillation in the SPORTIF trials. 2004; *J Am Coll Cardiol* 2004; 43 (Suppl):495A. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 2004.)
- A-47. Hriljac I, Olin JW, Teodorescu V, Gustavson S, **Halperin JL**. Measurement of resting ankle brachial index may not accurately identify disease in patients with signs or symptoms of peripheral arterial disease. *J Am Coll Cardiol* 2004; 43 (Suppl):459A. Presented at the 53rd Annual Scientific Sessions of the American College of Cardiology, New Orleans, LA, March 2004.

Jonathan L. Halperin, M.D.**ABSTRACTS** – continued

- A-48. Gombert-Maitland M, **Halperin JL**, Feyzi J, DeMets D, Wenger NK. Elevated risk of myocardial infarction associated with COX-2 inhibitor therapy in anticoagulated patients with atrial fibrillation in the SPORTIF III & V trials. 2005; (presented at the annual scientific sessions of the European Society of Cardiology, Stockholm, Sweden, September 6, 2005 Poster Session 306, Abstract No. 84078).
- A-49. Olin JW, Hiatt WR, Mohler ER, Creager MA, **Halperin, JL**, Hirsch AT, Roberts R, Weitz J, Gent A. SIMPADICO: A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial disease. *J Am Coll Cardiol* 2006 (presented at the Annual Scientific Sessions of the American College of Cardiology, Atlanta, GA, March 12, 2006).
- A-50. Büller H on behalf of the AMADEUS Investigators. Once-weekly subcutaneous idraparinux (anti-Xa) versus oral vitamin K antagonist therapy for prevention of thromboembolic events in patients with atrial fibrillation. *Thromb Haemost* 2007; Abstract O-W-054. (Presented at the XXI Scientific Congress of the International Society on Thrombosis and Haemostasis, Geneva, Switzerland, July 2007)
- A-51. Lubitz SA, Scott SA, Rothlauf EB, Agarwal A, Peter I, Doheny D, van der Zee S, Jaremko M, Desnick R, **Halperin JL**. Comparison of gene-based warfarin dosing algorithms in a multi-ethnic population. *J Am Coll Cardiol* 2009; 53: 448 (presented at the 58th Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 2009).
- A-52. Elmariah S, O'Brien KD, Budoff MJ, Vogel-Claussen J, Delaney JAC, Fuster V, Kronmal RA, **Halperin JL**. The relationship of bisphosphonate use to the prevalence of aortic valve calcification in women. The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol* 2009; (presented at the 58th Annual Scientific Sessions of the American College of Cardiology, Orlando, FL, March 2009).
- A-53. Patel M, Becker R, Breithardt G, Hacke W, **Halperin JL**, Hankey G, Mahaffey K, Singer D, Califf R, Fox K. Rationale and design of the ROCKET AF study: comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation. *Eur Heart J* 2009; 30 (Suppl): 705. (Presented at the annual scientific congress of the European Society of Cardiology, Barcelona, Spain, September 2009) <http://spo.escardio.org/abstract-book/presentation.aspx?id=69133>

Jonathan L. Halperin, M.D.

ABSTRACTS – continued

- A-54. Elmariah S, Fuster V, Kronmal RA, Budoff MJ, Vogel-Claussen J, O'Brien KD, Delaney JAC, **Halperin JL**. Bisphosphonate use and the prevalence of cardiovascular calcification in women: The Multi-Ethnic Study of Atherosclerosis. *Circulation* 2009; 120 Suppl 2: S538, 1647 (Presented at the Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 2009).
- A-55. Baber U, Howard V, **Halperin JL**, Soliman BZ, Zhang X, McClellan W, Warnock DG, Muntner P. Association of atrial fibrillation with chronic kidney disease in the United States. *Circulation* 2009; 120 Suppl 2: S520, 1571 (Presented at the Annual Scientific Sessions of the American Heart Association, Orlando, FL, November 2009).
- A-56. Elmariah S, O'Brien KD, Budoff MJ, Bluemke DA, Delaney JAC, Fuster V, Kronmal RA, **Halperin JL**. Relationships between left ventricular mass and aortic valve calcification: The Multi-Ethnic Study of Atherosclerosis. *J Am Coll Cardiol* 2010; 55 Suppl 10-A; 1062-390. (Presented at the Annual Scientific Sessions of the American College of Cardiology, Atlanta GA, March 2010).
- A-57. Breithardt G, Bode C, Patel M, Becker R, Hacke W, **Halperin JL**, Hankey G, Mahaffey K, Singer D, Califf R, Fox K on behalf of the ROCKET AF investigators. Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation: Rationale and design of the ROCKET AF study. 2010; (Presented at the annual scientific congress of the German Society of Thrombosis Research, Nürnberg, Germany February 2010).
- A-58. Breithardt G, Bode C, Patel M, Becker R, Hacke W, **Halperin JL**, Hankey G, Mahaffey K, Singer D, Califf R, Fox K on behalf of the ROCKET AF investigators. Comparison of rivaroxaban with warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation: Rationale and design of the ROCKET AF study. 2010; (submitted for presentation at the annual scientific congress of the German Cardiac Society, Mannheim, Germany April 2010).
- A-60. Elmariah S, Fuster V, **Halperin JL**, Delaney JA, O'Brien KD, Kronmal RA, Budoff MJ, Vogel-Claussen J. Bisphosphonate use and the prevalence of cardiovascular calcification in women: the Multi-Ethnic Study of Atherosclerosis. *Clin Res* 2009; (to be presented at the Eastern Regional Meeting of the American Federation for Clinical Research, Washington, DC, April 5, 2010).

Jonathan L. Halperin, M.D.

ABSTRACTS – continued

- A-61. Elmariah S, Fuster V, **Halperin JL**, Delaney JA, O'Brien KD, Kronmal RA, Budoff MJ, Bluemke V, Valentin F. Relationship between left ventricular mass and aortic valve calcification: the Multi-Ethnic Study of Atherosclerosis. *Clin Res* 2009; (presented at the Eastern Regional Meeting of the American Federation for Clinical Research, Washington, DC, April 5, 2010).
- A-62. Elmariah S, Delaney JAC, Bluemke DA, Budoff MJ, O'Brien KD, Fuster V, Kronmal RA, **Halperin JL**. Increased left ventricular mass predicts incident aortic and mitral valve calcification: The Multi-Ethnic Study of Atherosclerosis. 2010; *Circulation* 122: suppl (presented at the Annual Scientific Sessions of the American Heart Association, Chicago, IL November 2010).
- A-63. Mahaffey KW, Fox KAA, Patel, M, Breithardt G, Bode C, Patel M, Becker R, Paolini JF, Califf RM, Hacke W, **Halperin JL**, Hankey G, Nessel C, Singer D for the ROCKET-AF Investigators. Stroke prevention using the oral direct Factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). 2010; *Circulation* 122: suppl (presented at the Annual Scientific Sessions of the American Heart Association, Chicago, IL November 2010).
- A-64. van der Zee S, Scott SA, Doheny D, Rothlauf EB, Peter I, Blanchard L, Kadian-Dodov D, Lubitz S, Desnick RJ, **Halperin JL**. Quantitative pharmacogenomics of the anticoagulant response to warfarin in healthy subjects. *J Am Coll Cardiol* 2011; suppl (in press; to be presented at the annual scientific sessions of the American College of Cardiology, New Orleans, LA, April 2011).
- A-65. Lip GYH, **Halperin JL**, Petersen P, Rodgers GM, Renfurm RW. Safety and tolerability of the oral Factor Xa inhibitor YM150 compared to warfarin in 1,297 patients with nonvalvular atrial fibrillation: A phase IIb dose confirmation study (OPAL-2). 2011; (submitted for publication)
- A-66. Rodgers GM, Renfurm RW, **Halperin JL**, Petersen P, Lip GYH. Efficacy of the oral FXa inhibitor, YM150, on biomarkers for thrombogenesis in 1,297 patients with non-valvular atrial fibrillation: Phase IIb dose confirmation study (OPAL-2). 2011; (submitted for publication)

Jonathan L. Halperin, M.D.

CORRESPONDENCE:

- L-1. Fuster V, Cohen M, **Halperin JL**. Physicians' Health Study: aspirin and primary prevention of coronary heart disease (reply). *N Engl J Med* 1989;321: 1828.
- L-2. Stroke Prevention in Atrial Fibrillation Investigators. Prevention of stroke in atrial fibrillation (reply). *N Engl J Med* 1990; 323: 483-484.
- L-3. Chesebro JH, Fuster V, **Halperin JL**. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation (reply). *N Engl J Med* 1991; 325: 131-132.
- L-3a. Lebowitz MG, Phelps R, **Halperin JL**. Occult pseudoxanthoma elasticum in patients with premature cardiovascular disease (reply). *N Engl J Med* 1994; 330: 793
- L-4. Hart RG, Pearce LA, **Halperin JL**, Miller VT. Aspirin in elderly atrial fibrillation patients. *Stroke* 1994; 25:1525-1526.
- L-5. Hart RG, Feinberg WM, **Halperin JL** on behalf of the Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention guidelines. *Ann Intern Med* 1995; 122:235-236.
- L-6. **Halperin JL**. Consultations and Comments: Antithrombotic therapy for atrial fibrillation. *Consultant* 1995; 35:1261-1262.
- L-7. McBride R., Hart RG, **Halperin JL** for the Stroke Prevention in Atrial Fibrillation Investigators. Patients with atrial fibrillation at low Risk of stroke (reply). *JAMA* 1998; 280: 882-883.
- L-8. Chan K-L, Pearce LA, **Halperin JL** for the Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with atrial fibrillation (reply). *Ann Intern Med* 1998; 129:748-749.
- L-9. Squire A, Langan, M-N, **Halperin JL**. Electrocardiographic artifact mimicking ventricular tachycardia. *N Engl J Med* 2000; 342:592.
- L-10. Gombert-Maitland M, **Halperin JL**. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. *N Engl J Med* 2003; 348: 1929.
- L-11. Executive Steering Committee for the SPORTIF Investigators. Trials and tribulations of non-inferiority: The ximelagatran experience. *J Am Coll Cardiol* 2006; 48:1058.

Jonathan L. Halperin, M.D.

CORRESPONDENCE – continued:

- L-12. Freudenberger RS, **Halperin JL**, Poole J, Anderson J, Hellkamp A, Mark DB, Lee KL, Bardy GH for the SCD-HeFT Investigators. Heart failure and thromboembolism: An analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) (reply). *Circulation* 2007.
- L-13. Lip, GYH, Frison L, **Halperin JL**, Lane D. Comparative analysis of the HAS-BLED score with other bleeding risk scores, using the Net Reclassification Improvement (NRI) and Integrated Discrimination Improvement (IDI) (reply). *J Am Coll Cardiol* 2011 (in press).

APPEARS THIS WAY ON ORIGINAL

Jonathan L. Halperin, M.D.

PUBLISHED LECTURES and SPEECHES:

- PL-1. **Halperin JL.** Atrial fibrillation and flutter: When to anticoagulate. American College of Cardiology 32nd Annual New York Cardiovascular Symposium. Delivered in New York, NY, December 1999. Boston: Cardiology Interactive; 2000 (CD-ROM).
- PL-2. **Halperin JL.** Identification and treatment of systemic atherosclerosis in patients with peripheral arterial disease. Pri-Med East Symposium: Evidence-based management of peripheral arterial disease and intermittent claudication. Delivered in Boston, MA, September 16, 2000. *Family Practice News*; suppl 2001.
- PL-3. **Halperin JL.** Antithrombotic therapy atrial fibrillation: New information and trials. American College of Cardiology 33rd Annual New York Cardiovascular Symposium. Delivered in New York, NY, December, 2000. Boston: Physician Education, Inc; 2001 (CD-ROM).
- PL-4. **Halperin JL.** On the Horizon: Advances in Prevention of Stroke in Atrial Fibrillation. American Heart Association 74th Scientific Sessions. Delivered in Anaheim, CA, November 10, 2001. Institute for Continuing Healthcare Education (<http://www.iche.edu>).
- PL-5. **Halperin JL.** Antithrombotic therapy atrial fibrillation: New information and trials. American College of Cardiology 34th Annual New York Cardiovascular Symposium. Delivered in New York, NY, December, 2001. Boston: Physician Education, Inc; 2002 (CD-ROM).
- PL-6. **Halperin JL.** An oral direct thrombin inhibitor for the prevention and treatment of thromboembolism. American Society of Hematology 43rd Annual Meeting. Delivered in Orlando, FL, December 7, 2001. Institute for Continuing Healthcare Education, <http://www.iche.edu>).
- PL-7. **Halperin JL.** Vascular medicine and biology: An evolving infrastructure. Presidential address, delivered at the 13th Annual Meeting of the Society for Vascular Medicine and Biology, Boston, MA, June 7, 2002. *Vasc Med* 2002; 7:149-151.
- PL-8. **Halperin JL** on behalf of the Executive Steering Committee of the SPORTIF III Investigators. Stroke Prevention using the oral direct thrombin inhibitor, ximelagatran, in patients with nonvalvular atrial fibrillation. Delivered at the IIIrd plenary session of the American College of Cardiology Annual Scientific Sessions, Chicago, IL, April 2, 2003.

Jonathan L. Halperin, M.D.

PUBLISHED LECTURES and SPEECHES - continued

- PL-9. **Halperin JL.** Embracing a new paradigm to sustain vascular medicine. Presidential address, delivered at the 14th Annual Meeting of the Society for Vascular Medicine and Biology, Chicago, IL, June 6, 2003. *Vasc Med* 2003; 8:133-134.
- PL-10. **Halperin JL** on behalf of the Executive Steering Committee of the SPORTIF V Investigators. Stroke Prevention using the oral direct thrombin inhibitor, ximelagatran, in patients with nonvalvular atrial fibrillation. Delivered at the VIIth Plenary Session of the American Heart Association, 76th Annual Scientific Sessions, Orlando, FL, November 11, 2003.
- PL-11 **Halperin JL.** The next step in antithrombotic therapy: Oral thrombin inhibition. Cardiosource web site, American College of Cardiology Foundation and Elsevier, Inc. Delivered at the 36th Annual New York Cardiovascular Symposium, December 21, 2003. <http://www.accardio.org/cs/Programhlts/>.
- PL-12. **Halperin JL.** Atrial fibrillation: Priorities in clinical management. Delivered at Mount Sinai School of Medicine's 3rd Annual Program on Challenges in Internal Medicine, June 20, 2007. *Audio-Digest Internal Medicine* 2007; 54 (22), November 21, 2007.

APPEARS THIS WAY ON ORIGINAL

Jonathan L. Halperin, M.D.

INTERNET WEBCASTS and PUBLICATIONS:

- W-1. **Halperin JL.** Anticoagulation in atrial fibrillation. International Society of Holter and Noninvasive Electrocardiography Worldwide Internet Symposium on Atrial Fibrillation. 2005. http://af-symposium.org/lectures/jonathan_halperin_eng.mp3 [English]
http://af-symposium.org/lectures/jonathan_halperin_esp.mp3 [Spanish]
- W-2. **Halperin JL, Block PC.** Expert Opinion: ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic). American College of Cardiology CardioSource, posted December 14, 2005. <http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=220>
- W-3. Hohnloser SH, **Halperin, JL.** Anticoagulation in atrial fibrillation. CREATE Annual Advisory Meeting, Berlin, Germany, February 21, 2007; posted February 26, 2008. <http://www.theheart.org/article/836483.do>
- W-4. Harrington RA, Bode C, **Halperin JL**, Verheugt FWA. The Prevention and Treatment of Thromboembolic Disease: A Cardiologist's Perspective. European Society of Cardiology Annual Scientific Sessions, Munich, Germany, August 30, 2008; posted September 22, 2008. <http://www.theheart.org/article/897069.do>
- W-5. Kowey PR, **Halperin JL**, Yusuf S. Trial Design for Anticoagulation in Atrial Fibrillation Patients. American College of Cardiology Annual Scientific Sessions, March 30, 2009; posted April 13, 2009. <http://dme.cybersessions.com/conference/957517/>
- W-6. **Halperin JL**, Wallentin L, Oldgren J. Anticoagulation in Atrial Fibrillation and Acute Coronary Syndromes. American Heart Association Annual Scientific Sessions. November 17, 2009; posted February 16, 2010. <http://www.theheart.org/article/1046957.do>
- W-7. Wallentin L, Camm J, **Halperin JL**, Lip GYH. First Response: Warfarin Time in the Therapeutic Range: Time Out. American Heart Association Annual Scientific Sessions. November 17, 2009; posted February 26, 2010. <http://www.theheart.org/article/1028439.do>
- W-8. **Halperin JL**, Giugliano RP. Novel Oral Anticoagulants. Highlights from the American College of Cardiology Annual Scientific Sessions. March 16, 2010. <http://www.mdconferenceexpress.com>
- W-9. Halperin JL, Lévy S, Naccarelli GV. Stroke Prevention in Atrial Fibrillation: Controversies in Anticoagulant Care. Cardiostim congress, Nice, France, June 17, 2010; posted July 27, 2010. <http://www.theheart.org/article/1096823.do>

Jonathan L. Halperin, M.D.

INTERNET WEBCASTS and PUBLICATIONS – continued

- W-10. Halperin JL. Three questions about ticagrelor: Part 3. CardioExchange NEJM Practice Community. posted August 5, 2010. <http://www.cardioexchange.org/three-questions-about-ticagrelor-part-3-jonathan-halperin/>
- W-11. Halperin JL, Connolly SJ, Hohnloser SH, Lopes RD. How Do The New Anticoagulants for Stroke Prevention Stack Up? New Trial Results From ESC. posted October 4, 2010. <http://cme.medscape.com/viewarticle/729477>